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ABSTRACT
Ovarian cancer (OC) is the second most common gynecologic cancer;
however it is responsible for the most gynecologic cancer-related deaths.
Apoptosis evasion is an important mechanism in OC tumorigenesis, and the
prototypic anti-apoptotic protein, B-cell lymphoma 2 (Bcl-2), is often
overexpressed in OC tumors. Gaining a better understanding of the
mechanism(s) behind Bcl-2 overexpression and potential extra-anti-apoptotic
functions of Bcl-2 could elucidate the importance of elevated Bcl-2 in OC. In the
current study, I show through immunohistochemical analysis of normal, benign,
and OC tissue sections, that both epithelial and stromal Bcl-2 expression
decreases with OC progression. However, the number of Bcl-2-positive
lymphocyte nests and the size of these lymphocyte nests increase dramatically
with OC progression. Additionally, this study shows that lysophosphatidic acid
(LPA), a glycerophospholipid frequently elevated in serum and ascites fluid of OC
patients, upregulates Bcl-2 in OC cells. Bcl-2 enzyme-linked immunosorbant
assay (ELISA), western blot analysis, reverse transcriptase polymerase chain
reaction (RT-PCR), and luciferase reporter assays reveal that LPA increases Bcl2 promoter, messenger RNA (mRNA), and protein levels in OC cells, but not in
normal immortalized ovarian surface epithelial (IOSE) cells. LPA also increases
secreted levels of Bcl-2. In vitro human umbilical vein endothelial cell (HUVEC)
tube formation assays show that OC-derived Bcl-2 or recombinant human (rh)
xi

Bcl-2 promotes aberrant formation of tube-like structures. Though extracellular
Bcl-2 does not affect HUVEC cell viability, it may cause aberrant tube formation
by inhibiting HUVEC migration. Finally, Bcl-2 ELISA reveals that urinary Bcl-2
levels in OC patients are higher than those in normal individuals and patients
with benign gynecologic disease. Urinary Bcl-2 also complements serum CA125
when the two are compared in parallel samples. Furthermore, urinary Bcl-2
decreases following cytoreductive surgery. Altogether, the results suggest that
Bcl-2 is important in OC tumorigenesis and angiogenesis. Additionally, urinary
Bcl-2 may be a valuable non-invasive biomarker for OC diagnosis and/or
screening. Consequently, further elucidation of mechanisms of Bcl-2
overexpression and its extra-apoptotic functions could lead to improved
treatment and diagnostic strategies for OC patients.

xii

CHAPTER I:
INTRODUCTION

Ovarian Cancer
Ovarian cancer (OC) is the deadliest disease affecting the female genital
tract and ranks fifth in causes of cancer related death in women in the United
States. For 2010, the American Cancer Society predicts that the United States
will have an estimated 21,880 new cases of OC and 13,850 deaths due to OC
[1]. The OC annual worldwide incidence and mortality has been estimated to be
190,000 and 114,000 respectively [2]. According to the American Cancer
Society, a woman has a 1.4% (1 in 72) chance of developing OC during her life
and a 1.05% chance of dying from the disease [3]. A woman’s risk of developing
OC increases with age, particularly after menopause. Approximately 90% of the
women who get OC are over the age of 40, and over half of all OCs occur in
women over the age of 63 [3].

Ovarian Surface Epithelium
The ovaries are a pair of almond-shaped reproductive glands found on
each side of a woman’s uterus. Each ovary is surrounded by a fibrous tunica
albuginea, which is covered externally by a layer of cuboidal epithelial cells: the
ovarian surface epithelium (OSE). The OSE is mesodermally derived and, in
1

early embryonic development, forms part of the lining for the intraembryonic
coelom, termed the coelomic epithelium. The gonadal ridge is covered by this
coelomic epithelium, which has the capacity to differentiate along several
pathways. The Mullerian ducts develop as invaginations of the coelomic
epithelium and give rise to the epithelial lining of the future fallopian tubes,
uterus, and upper vagina [4]. As the coelomic epithelium proliferates, it forms
cords that infiltrate the ovarian cortex and give rise to the granulosa cells in the
primordial follicles [4]. The OSE overlies the follicles and the two are separated
by ovarian stroma. The OSE and stroma are separated by a basement
membrane. The OSE and basement membrane have a tenuous attachment,
which can be disrupted by the slightest of mechanical forces [4].

The Origins of OC
The OSE was originally coined the term germinal epithelium which is a
misnomer because it does not give rise to ova [5]. In adult females, the OSE is a
monolayered squamous-to-cuboidal epithelium, which ruptures during ovulatory
cycles, allowing a mature follicle to escape, and must, therefore, undergo wound
repair while exposed to estrogen-rich follicular fluid [6, 7]. OC can arise from
ovarian germ cells, connective tissue that generates reproductive hormones in
the ovaries (also known as the stroma), or the epithelial ovarian lining. Of these
origins, the most common is the OSE; therefore the most common form of OC is
epithelial ovarian cancer (EOC) [1, 7], and there are several hypotheses on the
mechanisms by which EOC arises.
2

The most widely accepted hypothesis is the “incessant ovulation” theory,
which suggests that surface epithelial ovarian neoplasms are the result of chronic
ovulation [7]. Repair of the ruptured OSE is initiated by follicular fluid, plasma,
cell debris, and surface epithelial cells which form a gel-like clot [8]. Invasion of
the clot by connective tissue fibers creates a scaffold for neighboring surface
epithelial cells, which migrate centripetally and cover the ovulatory wound in
three to five days. In the rabbit, the luxuriant reparative response of the OSE
often leads to the formation of papillary and cord-like growths [9]. In humans, the
repeated wound and healing process of the OSE during ovulation, along with its
ability to internalize potentially carcinogenic agents entering the peritoneal cavity
through the reproductive tract [10], may cause dysplasia in the epithelial ovarian
lining and eventually give rise to EOC. Reduced lifetime ovulations have been
related to lowering a woman’s risk of developing EOC [11]. Factors such as
early menarche, late menopause, nulliparity/low parity (with or without oral
contraceptives), hormone replacement therapy in menopause, family history of
breast or OC, and diets high in meat and fats have been reported to increase the
risk of a woman getting OC in her lifetime [12].
The second, less accepted, hypothesis about the origin of EOC is the
“gonadotrophin” theory which proposes that EOC arises from the formation of
inclusion cysts derived from invaginations of the OSE into the ovarian stroma [7].
Increased estrogen production, due to elevated levels of follicle stimulating
hormone and luteinizing hormone, contributes to malignant transformation by
stimulating the inclusion cyst epithelium to undergo rapid cell division [13].
3

Because both age-related frequencies of EOC and gonadotrophin concentrations
are considerably high in early menopause, this is the time when gonadotrophinrelated ovarian carcinogenesis seemingly occurs [14].
Lastly, an exfoliation theory has recently been described in which
(pre)malignant lesions are formed when exfoliated tubal epithelial cells become
entrapped within an ovarian stigma during the ovulatory process and undergo
genetic changes during mitosis [15]. This theory is based on several studies in
which preneoplastic lesions were found present in a high number of
prophylactically removed Fallopian tubes and findings that inclusion cysts in the
ovaries were often lined by cells that were indistinguishable from epithelial cells
lining the Fallopian tube [16-18]. These findings are not surprising given the
OSE undergoes a transformation to a Müllerian-type epithelium in ovarian
carcinomas while the Fallopian tubes have a native Müllerian epithelium [19].
Macroscopically normal Fallopian tubes in women who are predisposed to
developing OC commonly have hyperplastic and/or dysplastic changes upon
histological examination of their Fallopian tube epithelium [18]. These changes
include a ‘p53 signature’, described as strongly p53-positive, benign-appearing
epithelium in the distal Fallopian tube arising from a genotoxic injury such as
ovulation [20, 21]. Areas within Fallopian tubes containing a p53 signature can
then undergo cell proliferation and develop into tubal intraepithelial carcinoma
which can then expand in the Fallopian tube or metastasize to the peritoneum or
ovarian surface as a serous carcinoma [20]. To date, no single origin for EOC
has been determined, however, studies support all three theories.
4

Histologic Subtypes and Staging of Ovarian Tumors
All epithelial ovarian tumors demonstrate characteristics similar to those of
the Müllerian epithelium; however, they differ greatly in histopathologic features
[22]. There are four main histological subtypes of OC – serous, mucinous,
endometrioid, and clear cell. Epithelial cells in serous tumors resemble those of
the fallopian tubes. Given that serous tumors are the most common presentation
of ovarian neoplasm, they account for 50-60% of primary epithelial ovarian
tumors [23]. Mucinous tumor cells are similar to either endocervical or colonic
epithelium. They are cystic tumors with small chambers lined with mucinsecreting epithelial cells. They make up about 8-10% of primary epithelial
ovarian tumors [23]. Endometrioid tumor cells bear resemblance to endometrial
glands of the endometrium [23] and comprise about 10% of ovarian carcinomas
[24]. Clear cell carcinomas are composed of hobnail cells with clear cytoplasm.
These rare tumors account for only 5% of all ovarian tumors [24]. Less commonly
occurring OC subtypes include undifferentiated, mixed epithelial type, and
Brenner tumors.
Upon diagnosis, OC is staged according to the degree of tumor spread.
This is one of the best determinants for treatment and prognosis. Ovarian
tumors are staged according to the criteria set forth by the International
Federation of Gynaecology (FIGO) [25]. Tumors in stage I have growth confined
to the ovaries. Stage II tumors are limited to the pelvis. Tumors classified as
stage III have growth extending to the abdominal cavity. Lastly, stage IV tumors
5

have metastases to distant sites. Ovarian tumors are also given a histological
grade according to their architectural and nuclear abnormalities. Grade I tumors
are well differentiated. Grade II tumors are moderately differentiated. Grade III
tumors are poorly differentiated. Quite naturally, women presenting with tumors
of a higher grade and stage tend to have a poor prognosis.

Diagnostic Tools for OC
Significance of Early Detection of OC
Women diagnosed with OC have an overall 5-year survival rate of only
45% [1, 7]. There is a dramatic increase to a 5-year survival rate of 94% when
OC is diagnosed at an early stage, but this only occurs in 19% of reported cases
[7]. Among women with advanced OC which has metastasized at the time of
diagnosis, the survival rate declines sharply to about 28% [26]. This is generally
attributed to the fact that OC is often asymptomatic and there is no screening
marker available for use in the general public. Late diagnoses result in
discovering the disease after it has metastasized to other areas of the body, in
turn, making it more difficult to treat. Because of this, a diagnostic test is greatly
needed for OC that has high sensitivity as well as specificity. CA125 is currently
the only Food and Drug Administration (FDA)-approved blood test for the
detection of OC. Despite advances in research, the outlook of OC detection at
early stages remains bleak. When diagnosed in stage I, currently available
therapy can cure 90% of OC cases. On the other hand, 20% or less stage III and
stage IV OC cases can be cured. Currently, only about 20% of OCs are
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diagnosed in stage I, indicating a need for detection of preclinical disease at an
earlier stage [7]. Research suggests that occult primary tumors spend over 4
years as in situ, stage I/II cancers and about 1 year as stage III/IV cancers prior
to becoming clinically apparent [27]. Detection of OC at the preclinical stage may
help improve its cure and survival rates.

Criteria for Early Detection Screening
Ideally, screening for early detection of disease is most useful if there is a
pre-symptomatic stage where the treatment is more effective than if given after
symptoms emerge. Effective screening should be readily available, acceptable
to patients, and reasonably inexpensive. Of most importance, the screening
tests must have a sensitivity high enough to detect a significant portion of all
existing cases in the population while having a sufficiently high specificity and
positive predictive value (PPV) to avoid generating an excessive number of falsepositives. The consequence of a positive screening test for OC results in some
type of surgical intervention such as a laparoscopy or laparotomy. Given the low
incidence of OC, even in postmenopausal women, of only 1 in 2500 women per
year, an ideal screening strategy would have a sensitivity greater than 75% for
early stage disease with a specificity of 99.6% to yield a positive predictive value
of 10% [28]. This means that for every 10 laparotomies performed, one would
result in OC detection.

7

Screening Strategies
Cancer antigen (CA) 125 has been the most widely studied OC marker for
over two decades. CA125 is expressed by fetal amniotic and coelomic
epithelium. It is expressed in adult tissues derived from coelomic (pericardium,
peritoneum, and mesothelial cells of the pleura) and Müllerian epithelium (tubal,
endocervical, and endometrial). CA125 is not expressed in the surface
epithelium of normal fetal and adult ovaries; however, it is present in metaplastic
areas, papillar excrescences, and inclusion cysts [29]. The CA125 antigen
carries two major antigenic domains: A (binds monoclonal antibody OC125) and
B (binds monoclonal antibody M11) [30]. The original clinical assay for serum
CA125 quantification was a homologous assay that only utilized the OC125
antibody. The current CA125 immunoassay (CA125 II) is a heterologous assay
that uses both the OC125 and M11 antibodies. The current assay has a reduced
interassay variation and is, therefore, preferred over the original homologous
assay [31]. Investigations in the use of CA125 as a biomarker for OC began
when CA125 levels over 35 U/mL were observed in ~83% of patients with EOC
[32, 33]. Elevated CA125 levels were later found to be present in women 5 years
prior to their diagnosis of OC, suggesting that CA125 may be of use as a marker
of disease in the preclinical asymptomatic phase of OC [34]. Elevated serum
CA125 levels are most strongly associated with serous OC, which accounts for
the majority of clinical OC cases. However, CA125 is not a useful screening
marker due to high instances of false-positives and false-negatives. Many
factors can influence CA125 levels, including presence of other cancers, benign
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disease, age, menses, hysterectomy, smoking history, race/ethnicity, and obesity
[7, 35, 36]. Significant progress has been made in identifying potential
biomarkers for the early detection of OC with the use of mass spectrometric
protein profiling and other novel technologies. Currently, mathematical
techniques are being developed to analyze combinations of marker levels in an
attempt to improve sensitivity and specificity.

B-cell Lymphoma 2
The B-cell lymphoma 2 (Bcl-2) gene was originally coined in 1986 as the
oncogene product associated with the translocation t(14;18) [37, 38]. As a result
of the translocation t(14;18), the Bcl-2 gene at chromosome segment 18q21 is
juxtaposed with the immunoglobulin heavy chain locus at 14q32. This
translocation was originally discovered in a number of follicular lymphomas and
resulted in deregulated expression of Bcl-2. The anti-apoptotic effect of Bcl-2
was established when its overexpression was shown to promote survival in
interleukin-3-dependent cells in the absence of the cytokine [39]. The cloning of
Bcl-2 homologous proteins Bax (Bcl-2-associated X) [40] and Bcl-x [41] in 1993
lead to the discovery of a family of Bcl-2-like proteins which did not always play
an anti-apoptotic role in cell survival.

The Bcl-2 Family
All Bcl-2 family members are made up of one or more of the four Bcl-2
homology (BH) domains (Figure 1). Each BH domain has a unique function [42]:
9

Figure 1. Bcl-2 family members are made up of one or more Bcl-2
homology (BH) domains. The BH domains serve different functions: BH1 and
BH2 are for death suppression and pore formation, BH3 has death-promoting
activity, BH4 has death repressor activity. Most Bcl-2 family members also have
a c-terminal transmembrane (TM) domain, which targets them to the outer
mitochondrial, endoplasmic reticulum, or outer nuclear envelope membrane.
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BH1 and BH2 are responsible for death suppression (by binding to death agonist
Bcl-2 family members) and pore formation; BH3 has death-promoting activity;
BH4 has death repressor activity. Most Bcl-2 family members also have a Cterminal transmembrane domain, which targets them primarily to the outer
mitochondrial membrane, endoplasmic reticulum (ER) membrane, and the outer
nuclear envelope [43, 44]. Anti-apoptotic Bcl-2 proteins contain all four BH
domains and include the Bcl-2-related A1 (Bcl-2A1), Bcl-2, Bcl-2-related gene,
long isoform (Bcl-XL), myeloid cell leukemia 1 (Mcl-1), and Bcl-2-Like-2 (Bcl2l2)
protein which is also known as Bcl-w. These members preserve the integrity of
the outer mitochondrial membrane by forming heterodimers with their proapoptotic counterparts, thus directly inhibiting their activity. The pro-apoptotic
Bcl-2 family members are divided into subfamilies of effectors and BH3-only
proteins. The effector pro-apoptotic proteins include Bcl-2 antagonist killer 1
(Bak) and Bcl-2-associated x protein (Bax). Like the anti-apoptotic proteins, they
include all four BH domains. When activated, these proteins homodimerize and
permeabilize the outer mitochondrial membrane, resulting in release of
cytochrome c, and ultimately, apoptosis. BH3-only proteins are further
subdivided based on their ability to interact with only anti-apoptotic family
members or both the anti-apoptotic proteins and the effectors. BH3-only
members that only bind apoptotic family members are referred to as “sensitizer”
or “derepressor” BH3-only proteins and include the Bcl-2 antagonist of cell death
(Bad) and Noxa proteins. These BH3-only proteins are able to form
heterodimers with anti-apoptotic members, thus antagonizing their survival
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function; however, these proteins are incapable of promoting cell death
autonomously [42]. The BH3-only proteins, Bcl-2 interacting domain death
agonist (Bid) and Bcl-2-interacting mediator of cell death (Bim), are capable of
interacting with both the anti-apoptotic and effector Bcl-2 family members. They
can directly induce Bak and Bad oligomerization and permeabilization of the
outer mitochondrial membrane. These BH3-only proteins are called “direct
activators”. The Bcl-2 family members all work collectively to regulate the
process of apoptosis.

Bcl-2 and Apoptosis
Apoptosis evasion is a key hallmark of cancer [45]. Apoptosis is the
strategic and neat process by which a cell commits suicide. It is much tidier than
necrotic cell death which causes swelling and rupture of cells, leading to
inflammation in surrounding tissue. On the other hand, the apoptotic process
involves three orderly phases: the induction phase, the commitment/execution
phase, and the degradation phase. The induction phase begins when the cell
receives a death stimulus such as physical damage, exposure to chemotoxins, or
growth-factor withdrawal. The commitment/execution phase of apoptosis
signaling involves decreased cell volume with membrane blebbing and chromatin
condensation. This reduces cells to shriveled corpses, which are then rapidly
phagocytosed, signifying the degradation phase. Apoptosis is essential in
controlling cell number, removal of aged, autoimmune, or damaged cells, and
differentiation. The formation of many types of malignant tumors involves
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alteration of apoptotic regulation. The culprit is often overexpression of antiapoptotic proteins, resulting in a decrease in apoptosis, and, therefore,
uncontrolled cell proliferation [46-48]. The Bcl-2 family of proteins plays a central
role in the promotion and suppression of apoptosis, acting primarily at the
execution phase. This extensive family of proteins regulates cytochrome c
release from the mitochondria by decreasing (anti-apoptotic members, i.e. Bcl-XL,
Bcl-2) or increasing (pro-apoptotic members, i.e. Bax, Bad, Bim) its permeability
transition. Cytochrome c release from the mitochondria results in a cascade of
caspase activations and, ultimately, apoptosis.

Bcl-2 and OC
Bcl-2 has been established as a unique oncogene which prevents
programmed cell death and does not play a role in promoting proliferation [49].
Much evidence shows that Bcl-2 is localized to the mitochondrial outer
membrane, though it has also been found to be present in the smooth ER as well
as the perinuclear membrane. Its anti-apoptotic property has been attributed to
its ability to inhibit release of cytochrome c from the mitochondria, thus inhibiting
downstream activation of caspases and ultimately apoptosis. Overexpression of
wildtype Bcl-2 has been reported to contribute to neoplastic transformation
through inhibition of apoptosis [48]. Additionally, Bcl-2 overexpression in OC has
been associated with chemoresistance. Bcl-2 is associated with a favorable
prognosis in non-small cell lung cancer [50], colorectal cancer [51], and breast
cancer [52], whereas it is associated with poor prognosis in acute myeloid
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leukemia [53], large B-cell lymphoma [54], and prostate cancer [55]. Several
studies have found that EOC tissues [48, 56-60] as well as OC cell lines [57]
express considerable amounts of the proto-oncogene Bcl-2, however, its
prognostic significance in OC remains controversial. Though upregulation of Bcl2 in OC has been identified, the molecular mechanisms regulating Bcl-2
overexpression as well as potential extra-apoptotic consequences of Bcl-2
overexpression remain unknown.
The most commonly used chemotherapeutic treatment in OC patients is a
combination of platinum (i.e. cisplatin, carboplatin) and taxane drugs (i.e.
paclitaxel, docetaxel) [61]. The ability of OC to develop resistance to these
drugs, especially platinum drugs, is a major dilemma to both patients and their
physicians. Though there have been a number of studies performed to see if
Bcl-2 expression has an effect on OC resistance to platinum-based
chemotherapy, the results have not been consistent [58].

Lysophosphatidic Acid
Lysophosphatidic acid (LPA; 1-acyl-2-hydroxy[lyso]-sn-glycero-3phosphate) is the simplest glycerophospholipid and has been shown to have an
extensive range of biological activities. There are currently eight known LPAresponsive G protein-coupled receptors (GPCR). LPA activates receptors in the
G protein-coupled family of receptors encoded by the endothelial differentiation
genes (EDG), specifically, LPA1/EDG2, LPA2/EDG4, and LPA3/EDG7 [62-68]
(Figure 2). More recent studies have shown that LPA also activates receptors
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Figure 2. LPA binds to EDG family receptors EDG2, EDG4, and EDG7,
which are coupled to G-proteins, and activates multiple downstream
effector pathways. Gi and Gq activate PLC, resulting in generation of
diacylglycerol (DAG) and inositol triphosphate (IP3). DAG activates protein
kinase C (PKC), and IP3 mobilizes intracellular calcium ([Ca2+]i). Gi inhibits
adenylyl cyclase (AC) and thus cyclic adenosine monophosphate (cAMP).
Alternatively, Gi activates the Ras/mitogen-activated protein kinase (MAPK)
pathway. Gi also activates phosphoinositide 3-kinase (PI3K), which activates Akt
and Rac. Activation of Rho by G12/13 leads to subsequent activation of serum
response factor (SRF) and Rho-associated kinase (ROCK).
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LPA4/p2y9/GPR23, LPA5/GPR92, LPA6/GPR87, LPA7/p2y5, and LPA8/p2y10 in
the purinergic receptor cluster of GPCR [69-72], which are structurally distinct
from the EDG receptors.

EDG Family LPA Receptors
EDG receptors have been shown to exert their effects by coupling to the G
proteins Gi/o, G12/13, and Gq. Under physiological conditions the EDG receptors
have not been shown to couple to Gs. LPA stimulation leads to EDG2 coupling
to mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase
(ERK), resulting in cell proliferation [73]. This effect is blocked by pertussis toxin
(PTX), a Gi/o inhibitor, indicating that Gi/o mediates this response. Stimulation of
EDG2 also causes Gi/o-mediated inhibition of adenylyl cyclase (AC) [62, 74, 75]
Additionally, EDG2 causes Gq-mediated phospholipase C (PLC) activation, which
is PTX-insensitive and G12/13-mediated Rho activation, which can be inhibited by
botulinum C3 toxin [76-78]. Activation of the Rho-dependent signal cascade
results in cell rounding and neurite retraction in neuronal cells and stress fiber
formation in fibroblasts, contributing to LPA’s ability to cause changes in cell
morphology [62, 77]. EDG4 and EDG7 receptors have signaling properties
similar to EDG2, however, EDG7 is not coupled to the Rho pathway, whereas
this is not the case for EDG2 and EDG4 receptors [78]. Lastly, EDG4 and EGD7
receptors also couple to Gq, resulting in mobilization of intracellular Ca2+ [66, 67,
75].
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The EDG family LPA receptors have been found to be differentially
expressed according to tissue type. EDG2 is expressed in almost all tissues with
the greatest abundance in organs including the brain, ovary, and heart and the
lowest abundance in the liver, lung, peripheral blood leukocytes, and thymus
[66]. EDG4 is expressed greatest in peripheral blood leukocytes and testes with
less expression in pancreas, spleen, thymus, and prostate. However, in tissues
were EDG2 is expressed abundantly: brain, heart, placenta, ovary, and digestive
tract, EDG4 is virtually undetectable [66]. EDG7 expression is most abundant in
prostate, testes, pancreas, and heart, with moderate expression in the lung and
ovary [67]. EDG7 is undetectable in other tissues.

Non-EDG Family LPA Receptors
Several human GPCRs have recently been de-orphanized, resulting in the
discovery of a group of LPA receptors closely related to the purinergic P2Y
receptors. LPA4/p2y9/GPR23 was found when Chinese hamster ovary cells
stably transfected with orphan GPCRs were screened with 198 lipids.
LPA4/p2y9/GPR23 was able to be activated by 1-oleoyl-LPA-mediated coupling
to Gs, leading to induction of intracellular Ca2+ mobilization and cyclic adenosine
monophosphate (cAMP) formation [79]. Stimulation of cAMP formation via LPA4
was later found to be cell-type dependent [80]. Further studies showed that
stimulation of LPA4 led to phenomena similar to what happens with EDG receptor
activation, such as neurite retraction and cell aggregation as well as an antimigratory effect that seems to involve activation of Rho through G12/13 [80-83].
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LPA5/GPR92 was identified when its expression lead to G12/13 and Rho-mediated
neurite retraction, receptor internalization, increased [3H]-LPA binding to
membrane fractions, increased cAMP accumulation, and intracellular Ca2+
mobilization via Gq in both rat neuroblastoma and hepatoma cells [84]. Deorphanization of the LPA7/p2y5 receptor divulged its involvement in the
regulation of hair follicle development and hair growth [70, 85]. LPA stimulation
also revealed cAMP response element driven transcription in cells stably and
transiently expressing LPA7. LPA6/GPR87 and LPA8/p2y10 have also been
suggested to be LPA receptors [71, 72], however, because the cell types used in
the studies had intrinsic responses to LPA, further studies are suggested using
cell lines that are hyposensitive to LPA to confirm that these receptors have not
been misidentified [86].

Biological Functions of LPA
LPA production in multiple cell types, including OC cell lines, has been
reported. LPA has several pleiotropic biological functions in a number of cell
types. Some roles of LPA include mediation in wound healing and tissue
regeneration, stimulation of cell proliferation, cell survival, platelet aggregation,
and tumor cell invasion. LPA plays a role in embryonic development of the
nervous system. Stimulation of EDG2 by LPA in oligodendrocytes and Schwann
cells protects these cells from apoptosis through activation of the
phosphatidylinositol 3-kinase (PI3K) /Akt cell survival signal pathway. LPA is
able to induce cell cycle-dependent morphological changes and cell migration via
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EDG2 stimulation in cortical neuroblasts in vitro (reviewed in [78]). LPAmediated EDG4 activation is suspected to modulate neurite formation and control
migration of post-mitotic differentiating neurons to their final destination.
Furthermore, LPA has been shown to mediate neuronal cell MAPK activation and
arachidonic acid release via all three EDG receptors [75].
LPA is elevated in both the plasma and ascites fluid of OC patients [87-89]
and has been proposed as a diagnostic tool for OC [89]. EDG2 expression is
exceptionally high in slowly proliferating and cisplatin-resistant cell lines, whereas
it is virtually absent from rapidly proliferating and cisplatin-sensitive OC cell lines.
Therefore, it has been suggested that this LPA receptor plays a role in negative
regulation of ovarian epithelial cell growth and metastasis [90]. OC cell lines
secrete considerable amounts of LPA into their culture medium which can further
stimulate LPA production in an autocrine fashion via EDG4 and EDG7 receptors.
These receptors are overexpressed in OC cells in comparison to normal and
even immortalized ovarian surface epithelial cells [91, 92]. LPA activation of
EDG7 is proposed to be related to OC cell growth [92, 93] and proliferation [92].
This is supported by evidence confirming significantly higher expression of EDG7
in immature teratoma, endometrioid adenocarcinoma, and serous
cystadenocarcinoma tissues compared to normal ovarian tissue [94]. However,
there are no significant differences in EDG7 expression among clear cell
adenocarcinoma, mucinous cystadenocarcinoma, and undifferentiated
adenocarcinoma tissue when compared to its expression in normal ovarian
tissue. In addition to its role in cell proliferation, LPA has also been shown to
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elicit anti-apoptotic activity through upregulation of Bcl-2 at both mRNA and
protein levels in intestinal epithelial cells [95]. It is likely that LPA-mediated Bcl-2
upregulation occurs in OC because the ascites fluid of OC patients is rich in LPA
[87, 88] and ovarian tumors also overexpress Bcl-2 [48, 56-60].

Angiogenesis
Angiogenesis is the formation of new blood vessels from preexisting
vasculature. Tumor vascularization plays a vital part in OC progression and
prognosis given that ovarian carcinomas are often associated with multifocal
intraperitoneal spreading along with profound neovascularization.

Vascular Endothelial Growth Factor
The first angiogenic factor was postulated in 1970 when Folkman
discovered a soluble protein that was secreted from both human and animal solid
tumors which had a mitogenic effect on capillary endothelial cells [96]. He and
his colleagues termed this protein tumor angiogenesis factor (TAF) and
suggested that it could be blocked to arrest the growth of solid tumors. TAF was
later identified as Basic Fibroblast Growth Factor (bFGF), a growth factor which
stimulated the growth of several cell types, including endothelial cells, and whose
angiogenic properties had already been recognized [97]. Later, one of the most
potent and most studied angiogenic factors, vascular endothelial growth factor
(VEGF), was identified when Senger et al. discovered its presence in the culture
supernatant and ascites of rodent tumors [98]. The VEGF-related gene family
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consists of six secreted glycoproteins referred to as VEGF-A, VEGF-B, VEGF-C,
VEGF-D, VEGF-E and placental growth factors-1 and -2 [99]. VEGF-A the
prototype family member, is often referred to as VEGF. Alternative splicing of the
VEGF gene results in four mature isoforms containing 121, 165, 189, and 206
amino acids [100, 101]. The 165 amino acid isoform is most commonly
expressed in both normal and tumor cells. VEGF is a key regulator of blood
vessel growth and was originally given the name vascular permeability factor
(VPF) due to its ability to increase microvascular permeability to circulating
macromolecules [98, 102, 103]. VEGF has been shown to play a role in
endothelial cell proliferation and modeling of the vessel wall in both normal and
abnormal circumstances [99, 104].

Mechanisms of Angiogenesis
Angiogenesis is a highly regulated multi-step process. It begins with
vasodilation and VEGF-mediated vascular permeabilization, which allows
extravasation of plasma proteins which deposit a temporary scaffold for migrating
endothelial cells (reviewed in[105]). Angiopoietin (Ang) 2 (an inhibitor of Tie2
signaling) and various proteinases facilitate detachment of smooth muscle cells
and degradation of the extracellular matrix, respectively, contributing to
destabilization of mature blood vessels, a process required for the release and
migration of endothelial cells [105]. Several molecules, including tumor necrosis
factor α, transforming growth factor (TGF) β1, members of the chemokine system
and the platelet-derived growth factor, FGF, and VEFG families, stimulate the
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migration and proliferation of endothelial cells. Once endothelial cells assemble
as a solid cord, they eventually acquire a lumen, which is dependent on VEGF
family members, Ang1, integrins (αvβ3 or αvβ5) and the myocyte enhancer binding
factor 2C [105]. Ang1, a ligand of the endothelial Tie2 receptor, is a natural
inhibitor of vascular permeability and tightens preexisting blood vessels, hence, it
plays a role in vessel maturation. Upon assemblage of vessels, endothelial cells
undergo differentiation and remodeling. Maturation of the vascular network into a
system with larger and smaller vessels involves ‘pruning’ and remodeling of
capillary-like tubules with uniform size, and irregular organization into a
structured network of branching vessels [105]. Excess endothelial cells are lost
during the remodeling process [106]. Though the molecular mechanisms of
remodeling remain to be elucidated, it has recently been suggested that cell loss
during remodeling is due to apoptosis and is critical to proper remodeling of
endothelial cells and tube formation in vivo [107].
Besides the above-mentioned mechanism, which is classically referred to
as sprouting angiogenesis, alternate angiogenic mechanisms have been
described in tumors, namely vessel co-option and vasculogenic mimicry. Vessel
co-option occurs when vascular supply is inadequate for a cell population,
resulting in migration and relocation of the tumor cells to a preexisting capillary
[108]. Pro-angiogenic factors are secreted under hypoxic conditions, stimulating
the proliferation and migration of endothelial cells from nearby vessels to begin
neovascularization. Vascular mimicry is a more recent and highly debated
phenomenon whereby a collection of multipotential cancer cells differentiates into
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endothelial cell-mimics, which line the vascular channels, as opposed to
endothelial cells [109-111].
Regardless of their route of formation, tumor blood vessels differ
tremendously from their normal counterparts. They typically possess abnormal
branching patterns, irregular diameters, corkscrew structures, and blind ends and
can, therefore, not be classified as arterioles, capillaries, or venules [112].
Tumor vessels also display avid binding and uptake of cationic liposomes, and
expression of integrins, growth factors, and receptors that vary from those of
normal vessels [106, 108, 113]. Unusual leakiness of nascent vessels also
distinguishes them from normal vasculature and aids the process of metastasis.
The fenestrated basement membranes of tumor vessels allows increased
accessibility to stray tumor cells [114]. Though more work needs to be done,
studies on vessel permeability have proven to be key in the advancement of
chemotherapy delivery and improving anti-angiogenic therapies.
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CENTRAL HYPOTHESIS

Bcl-2 has been shown to be elevated in a number of solid tumors, including OCs.
Though upregulation of Bcl-2 in OC has been identified, detailed information on
the molecular mechanisms responsible for Bcl-2 upregulation and the potential
for non-anti-apoptotic Bcl-2-dependent activities remains unclear. LPA is also
overexpressed in ovarian tumors and has been shown to upregulate Bcl-2 in
other epithelial tissues. I hypothesize that LPA, in part, drives the production and
secretion of Bcl-2 in OC cells and that extracellular Bcl-2 has novel effects on
ovarian tumors outside of its known anti-apoptotic activity.

SPECIFIC AIMS

1. Confirm the clinical correlation between Bcl-2 and OC progression.
2. Confirm that LPA, in part, drives the production and secretion of Bcl-2 in OC
and determine the biological significance of elevated Bcl-2 in OC by
evaluating the role that extracellular Bcl-2 plays in angiogenesis.
3. Demonstrate that Bcl-2 may be used as a diagnostic tool in OC by evaluating
urinary Bcl-2 levels of OC patients, women with benign gynecologic disease,
and normal healthy volunteers.
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CHAPTER II:
BCL-2 EXPRESSION IS ALTERED WITH OVARIAN TUMOR PROGRESSION:
AN IMMUNOHISTOCHEMICAL EVALUATION

Abstract
OC is the most lethal gynecologic malignancy. The ovarian tumor
microenvironment is comprised of tumor cells, surrounding stroma, and
circulating lymphocytes, an important component of the immune response, in
tumors. Previous reports have shown that the anti-apoptotic protein Bcl-2 is
overexpressed in many solid neoplasms, including OCs, and contributes to
neoplastic transformation and drug-resistant disease, resulting in poor clinical
outcome. Likewise, studies indicate improved clinical outcome with increased
presence of lymphocytes. Therefore, I sought to examine Bcl-2 expression in
normal, benign, and cancerous ovarian tissues to determine the potential
relationship between epithelial and stromal Bcl-2 expression in conjunction with
the presence of lymphocytes for epithelial ovarian tumor progression. Ovarian
tissue sections were classified as normal (n=2), benign (n=17) or cancerous
(n=28) and immunohistochemically stained for Bcl-2. Bcl-2 expression was
assessed according to cellular localization, extent, and intensity of staining. The
number of lymphocyte nests as well as the number of lymphocytes within these
nests was counted. While Bcl-2 staining remained cytoplasmic, both percent and
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intensity of epithelial and stromal Bcl-2 staining decreased with tumor
progression. Further, the number of lymphocyte nests dramatically increased
with tumor progression. The data suggest alterations in Bcl-2 expression and
lymphocyte infiltration correlate with epithelial OC progression. Consequently,
Bcl-2 expression and lymphocyte status may be important for prognostic
outcome or useful targets for therapeutic intervention.

Introduction
OC currently ranks 5th in cancer related deaths among women in the
United States[1] in spite of advances in treatment. Despite an overall OC
survival rate of 45%, the five year survival rate for women diagnosed with OC in
its early stages is 94%, however these women only make up 19% of reported OC
cases [7]. This poor prognosis is, in part, due to a lack of symptoms at early
stages as well as lack of a screening marker available to the general public. The
OSE is generally believed to be the origin for the majority of epithelial OC cases
[115], though current reports of a fallopian tube origin for OC have emerged [15,
19]. Consequently, the etiology of OC is still poorly understood.
A basement membrane consisting mainly of collagenous connective tissue
separates the OSE, a modified mesothelium, from underlying ovarian stromal
tissue [116]. The OSE and stroma both synthesize and secrete components that
contribute to deposition of the basement membrane during postovulatory repair
[117]. Normal ovarian stroma also produces an array of growth factors,
including, but not limited to TGF-β1 and the hepatocyte growth factor (HGF)
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receptor c-Met that stimulate autocrine and paracrine-mediated proliferation of
the superjacent epithelium. These growth factors tend to be overexpressed in
many carcinomas, hence facilitating neoplastic growth [118]. Additionally,
stromal-epithelial interactions have been studied in cancers of the bladder,
breast, cervix, colon, prostate, and ovary [119-124] and have shown that stromal
cells influence epithelial cell growth as well as tumorigenesis.
In addition to the role of the tumor microenvironment, alterations in
apoptotic regulation promoting an anti-apoptotic phenotype also support tumor
progression. Specifically, Bcl-2, recognized as the prototypical anti-apoptotic
protein, is overexpressed in a number of solid tumors, including OC, and
contributes to neoplastic transformation through inhibition of apoptosis [48],
thereby promoting tumor survival.
In contrast, ovarian tumors can also elicit a marked host immune response
resulting in the influx of tumor infiltrating lymphocytes into the tumor which
recognize antigens expressed on ovarian tumors [125]. The presence of tumor
infiltrating lymphocytes in OC patients appears to confer a survival advantage
[126-128]; however, this immune response is not normally sufficient to inhibit
tumor growth over extended periods of time.
While several studies have previously examined Bcl-2 or the contribution
of tumor infiltrating lymphocytes separately for OC prognosis, I sought to further
determine the combined clinical relationship between Bcl-2 expression and
lymphocyte filtration for OC progression. To my knowledge, there have not been
any other similar studies to date. Therefore, given the close proximity of tumor
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cells, their surrounding stroma, and infiltrating lymphocytes, I analyzed the
immunohistochemical expression and histological localization of Bcl-2 in ovarian
the stromal and epithelial components of normal, benign, and cancer clinical
specimens as well as evaluated changes in lymphocyte populations with ovarian
tumor progression.

Materials and Methods

Tissue Specimens
With institutional approval, a previously existing tissue bank was utilized to
retrieve a cohort of de-identified women who had undergone primary surgery with
complete surgical staging for EOC or borderline tumors at the H. Lee Moffitt
Cancer Center between 2000 and 2001. This gynecologic oncology procedure
database was also used to select women who had undergone oophrectomy due
to cystadenoma or had their ovaries removed for unrelated pathology between
2000 and 2001. All tissue specimens were fixed with 10% formalin and paraffinembedded. Four micron sections were stained with haematoxylin and eosin (H &
E) and the slides were reviewed by a pathologist (SVN) to confirm histologic
diagnosis according to the FIGO classification system. The de-identified medical
records of these women were reviewed, and tumor pathology was correlated to
the immunohistochemical findings. From these observations, the selected
ovarian sections were given the following classifications: 2 normal, 17 benign
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cysts or cystadenomas, and 28 serous papillary carcinomas, though areas of
normal OSE were also present in 5 benign and 4 carcinoma sections.

Immunohistochemistry
For immunohistochemical studies, further formalin-fixed paraffin sections
were cut at 3 microns and dried overnight at room temperature then
deparaffinized and rehydrated. Sections were soaked in hydrogen peroxide to
block endogenous peroxidase activity. Microwave antigen retrieval was achieved
by placing slides in 1X solution of AR-10 (BioGenex #HK057-5K, San Ramon,
CA), boiling, and then microwaving for an additional 10 minutes. The specimens
were then immunostained on the Dako Autostainer (Dako North America, Inc.,
Carpinteria, CA) using Monoclonal Mouse Anti-Human Bcl-2 (Clone 124, Dako,
Carpinteria, CA) primary antibody (1:40) for 30 minutes and the Dako’s
EnVision™ + horse radish peroxidase (HRP) Mouse (DAB+) kit according to the
manufacturer’s instructions, then counterstained with modified Mayer’s
haematoxylin, dehydrated through graded alcohol, cleared with xylene, and
mounted with resinous mounting medium. In an effort to control variability, all
samples were stained at the same time and with the same lot of reagents.
Normal tonsil was used as an internal positive control while negative controls
were obtained by substitution of primary antibody with normal mouse serum.
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Staining Analysis
Immunohistochemical staining was evaluated independently by four
individuals (LP, NSA, PAK, and SVN). The pattern of Bcl-2 staining was
evaluated as nuclear or cytoplasmic. Amount of stromal and epithelial staining
was assessed as percent staining from each section and scored as having either
≤50% or >50% positive cells. Staining intensity was also evaluated and
classified as negative, weak, moderate, or intense staining. The presence of
lymphocyte nests in each section was also observed and counted by observing
assemblages of ten or more lymphocytes in 10 random viewings at a total
magnification of 100X. The number of lymphocytes in each observed nest was
also counted and grouped into 5 categories: <25, 25-50, 50-75, 75-100, or >100
lymphocytes per nest.

Statistical Analysis
SAS version 9.2 (SAS Institute, Cary, NC) was used for statistical analysis
of Bcl-2 staining in normal, benign, and cancerous tissue samples. Fisher’s
exact test was used to test for associations in extent of epithelial and stromal
staining between tumor types and staining intensity of epithelial and stromal
staining between tissue types. The Cochran–Mantel–Haenszel test was used to
test for independence between tissue type and lymphocyte nest size. The
generalized linear model, along with pair-wise comparison among tissue types
was used to test for differences in tissue type and the number of lymphocyte
nests present.
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Results
Immunohistochemical staining was performed on a total of 47 ovarian
tissue sections as characterized in table 1. The mean age of the sample
population was 62 years (range, 33-88 years) and no significant differences were
noted in age among categories. The predominant histologic type for malignant
tissue samples was serous (26/28), and patients typically presented with high
grade tumors (Grade 3, 19/28). The majority of the malignant samples were also
from patients with stage III OC (25/28). Samples classified as “other” included
follicular cysts and a cystadenofibroma.

Epithelial Bcl-2 Staining Decreases with OC Progression
All tissues in this study, with the exception of four poorly differentiated
serous papillary carcinomas, displayed some degree of epithelial and/or stromal
Bcl-2 staining. Bcl-2 staining was confined to the cytoplasm in epithelial and
stromal cells. While only 2 specimens were classified as normal, there were
areas of normal epithelia on 5 benign and 4 cancerous specimens. Due to the
small number of normal specimens procured, I included these additional areas in
normal epithelial analyses. Epithelial Bcl-2 staining was present in 91% (10/11)
normal, 100% (17/17) benign, and 79% (22/28) cancer specimens (Figure 3,
Table 2). Further, 65% (11/17) benign specimens showed epithelial Bcl-2
staining in more than 50% of their epithelial cells, whereas, 18% (2/11) and 29%
(8/28) normal and OC tissues, respectively, displayed epithelial Bcl-2 staining to
the same extent (Table 2). In the cancerous sections, extent of Bcl-2 epithelial
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TABLE 1. Characteristics of the study cohort.

Normal
(n=2)

Cysts
(n=4)

Cystadenomas
(n=13)

WD (Grade 1)
(n=3)

MD (Grade 2)
(n=6)

PD (Grade 3)
(n=19)

Age (years)
Mean (SD)
Range

57.5 (12.0)
49-66

58.0 (16.1)
48-81

65.0 (10.1)
49-79

48.7 (6.5)
42-55

64.8 (16.7)
33-76

Histology
Serous
Mucinous
Endometrioid
Other

N/A
N/A
N/A
N/A

1
0
0
3

11
1
0
1

1
0
2
0

6
0
0
0

19
0
0
0

Stage
I
II
III
IV

N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A

0
1
2
0

0
0
6
0

1
0
17
1

62.7 (14.5)
33-88

N/A indicates category was not applicable to those samples.
WD = well differentiated carcinoma, MD = moderately differentiated serous papillary carcinoma, PD = poorly differentiated
serous papillary carcinoma
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Figure 3. Bcl-2 staining is more extensive in cysts than normal and cancerous sections. Positive Bcl-2 staining in
epithelial cells of normal (A), follicular cyst (B), and moderately differentiated serous papillary carcinoma (C) sections.
(Original magnification: 200X).
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TABLE 2. Bcl-2 immunoreactivity in ovarian tissue sections.

Total

__% Positive Epithelium (n)__

___% Positive Stroma (n)___

Total

≤ 50%

> 50%

Total

≤ 50%

> 50%

Normal
Normal within Benign
Normal within Cancer
Total Normal

2
5
4
11

50 (1)
100 (5)
100 (4)
91 (10)

100 (2)
100 (5)
50 (2)
82 (9)

0
0
50 (2)
18 (2)

100 (2)
—
—
100 (2)

0
—
—
0

100 (2)
—
—
100 (2)

Cysts
Cystadenomas
Total Benign

4
13
17

100 (4)
100 (13)
100 (17)

25 (1)
38 (5)
35 (6)

75 (3)
62 (8)
65 (11)

50 (2)
92 (12)
82 (14)

75 (3)
62 (8)
65 (11)

25 (1)
38 (5)
35 (6)

WD
MD
PD
Total Cancerous

3
6
19
28

100 (3)
100 (6)
68 (13)
79 (22)

33 (1)
67 (4)
79 (15)
71 (20)

67 (2)
33 (2)
21 (4)
29 (8)

100 (3)
17 (1)
68 (13)
61 (17)

66 (2)
83 (5)
95 (18)
89 (25)

33 (1)
17 (1)
5 (1)
11 (3)

WD = well differentiated carcinoma, MD = moderately differentiated serous papillary carcinoma, PD = poorly differentiated
serous papillary carcinoma
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staining tended to decrease with increased tumor grade (Table 2, Figure 4).
More than 50% of the epithelial cells stained positive for Bcl-2 in 67% (2/3) of
well differentiated carcinomas (WD), 33% (2/6) of moderately differentiated
serous papillary carcinomas (MD), and 21% (4/19) of poorly differentiated serous
papillary carcinomas (PD) (Table 2, Figure 4). Though there was a trend, these
differences were not statistically significant. Similar to the extent of staining,
intensity of epithelial Bcl-2 staining was higher in benign samples, with 94%
(16/17) of benign sections showing an intensity of moderate or intense, while
64% (7/11) and 43% (12/28) normal and malignant sections, respectively,
showed an epithelial staining intensity of moderate or intense degree (Figure 5).
More specifically, the epithelial staining intensity in cystadenomas was
significantly higher than that in both MD and PD sections (P=0.02 and P<0.0001,
respectively), but not in WD sections. Comparison among the cancerous
samples showed that there was decreased epithelial Bcl-2 intensity with
advanced tumor grade (Figure 5); however, these differences did not reach
statistical significance.

Stromal Bcl-2 Staining Decreases with OC Progression
Like epithelial staining, stromal Bcl-2 staining also decreased with
malignant progression (Figure 6). One hundred percent (2/2) normal, 82%
(14/17) benign, and 61% (17/28) malignant samples stained positive for stromal
Bcl-2 (Table 2). While 100% (2/2) of the normal specimens were found to have a
positive Bcl-2 staining in more than 50% of the stromal cells, 35% (6/17) of
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Figure 4. Extent of epithelial Bcl-2 staining in ovarian tissues. Extent of
epithelial Bcl-2 staining was observed wholly in each section of normal (N), cyst
(Cy), cystadenoma (CyAd), well-differentiated serous papillary carcinoma (WD),
moderately-differentiated serous papillary carcinoma (MD), and poorlydifferentiated serous papillary carcinoma (PD) ovarian tissue and categorized as
either: ≤50% or >50% positive staining. Scored sections were graphed as a
percent according to total sections of each tumor type.
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Figure 5. Intensity of epithelial Bcl-2 staining decreases with tumor
progression. Intensity of epithelial Bcl-2 staining was observed wholly in each
section of normal (N), cyst (Cy), cystadenoma (CyAd), well-differentiated serous
papillary carcinoma (WD), moderately-differentiated serous papillary carcinoma
(MD), and poorly-differentiated serous papillary carcinoma (PD) ovarian tissue
and categorized as having negative, weak, moderate, or intense staining.
Scored sections were then graphed as a percent according to total sections of
each tumor type.
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Figure 6. Stromal Bcl-2 staining decreases with tumor progression. Stromal Bcl-2 staining in normal (A), serous
cystadenoma (B), and moderately differentiated serous papillary carcinoma (C) sections. (Original Magnification: 40X)
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benign tumors had Bcl-2 expression in more than 50% of the stromal cells
(Figure 7). In contrast, only 11% (3/28) of OC sections had more than 50% of
their stromal cells expressing Bcl-2 (Figure 7). Similar to extent of epithelial Bcl-2
staining, differences in extent of stromal Bcl-2 staining between tumor types were
not statistically significant, with the exception of PD samples having significantly
less staining than both normal and cystadenoma samples (P=0.1 and 0.03,
respectively). Stromal intensity was moderate in 100% (2/2) of the normal
tissues, and in 82% (14/17) benign tumors (Figure 8). However, moderate
stromal intensity decreased to 29% (8/28) in OC sections (Figure 8). Stromal
Bcl-2 intensity in cystadenomas was significantly different versus intensity in MD
and PD specimens (P=0.003 and P<0.0001, respectively), while stromal Bcl-2
intensity in cysts was not significantly different from any of the specimens.
Likewise, stromal intensity decreased with increased tumor grade with 100%
(3/3) WD, 17% (1/6) MD, and 21% (4/19) PD displaying moderate stromal
intensity for Bcl-2 staining (Figure 8). Additionally, PD stromal intensity was
significantly lower than MD (P=0.05).

Bcl-2-Positive Lymphocyte Nests Increase with OC Progression
In contrast, the average number of lymphocyte nests (defined as
aggregates of 10 or more lymphocytes) (Figure 9, Table 3) present per section
increased with malignant progression. While normal and benign samples both
averaged less than two lymphocyte nests per section, WD sections averaged
3.33 lymphocyte nests per section, and higher grades displayed significantly
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Figure 7. Extent of stromal Bcl-2 staining decreases with tumor
progression. Extent of stromal Bcl-2 staining was observed wholly in each
section of normal (N), cyst (Cy), cystadenoma (CyAd), well-differentiated serous
papillary carcinoma (WD), moderately-differentiated serous papillary carcinoma
(MD), and poorly-differentiated serous papillary carcinoma (PD) ovarian tissue
and categorized as either: 0% positive, <5% positive, 5-25% positive, 26-50%
positive, 51-75% positive, or >76% positive staining. Scored sections were
graphed as a percent according to total sections of each tumor type.
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Figure 8. Intensity of stromal Bcl-2 staining in ovarian tissues. Intensity of
stromal Bcl-2 staining was observed wholly in each section of normal (N), cyst
(Cy), cystadenoma (CyAd), well-differentiated serous papillary carcinoma (WD),
moderately-differentiated serous papillary carcinoma (MD), and poorlydifferentiated serous papillary carcinoma (PD) ovarian tissue and categorized as
having negative, weak, moderate, or intense staining. Scored sections were then
graphed as a percent according to total sections of each tumor type.
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Figure 9. Lymphocyte nests are more abundant in malignant sections. Bcl2 staining in a representative photo of a large lymphocyte nest in a poorly
differentiated serous papillary carcinoma tumor. (Magnified 100X)
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TABLE 3. Lymphocyte nests and number of lymphocytes in each nest according to tissue type.

Tumor Type

n

# Lymph
Nests*

<25

# Lymphocytes in Nests
25-50
50-75
75-100

>100

Average Lymph
Nests/Section*

Normal

2

0

0

0

0

0

0

0

Benign
Cyst
Cystadenoma
Total

4
13
17

6
13
19

1
8
9

3
1
4

2
2
4

0
1
1

0
1
1

1.50
1.00
1.12

Cancerous
WD
MD
PD
Total

3
6
19
28

10
46
149
205

1
11
23
35

4
11
25
40

3
9
23
35

1
2
12
15

1
13
66
80

3.33
7.67
7.84
7.32

*Lymph Nests = aggregates of 10 or more lymphocytes
WD = well differentiated carcinoma, MD = moderately differentiated serous papillary carcinoma, PD = poorly differentiated
serous papillary carcinoma
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more lymphocyte nests with MD (P=0.01) and PD (p=0.003) sections having
averages of 7.67 and 7.84 lymphocyte nests per section, respectively. Due to
small sample sizes within tissue subtypes, the samples were divided simply into
normal, benign, or cancerous to analyze differences in the sizes of lymphocyte
nests (Table 3). Interestingly, the size of lymphocyte nests also significantly
increased as tumors became cancerous (p=0.004). Additionally, lymphocyte
population may also be associated with cancer stage because the stage I and II
OC sections did not contain any lymphocyte nests and, with the exception of one
stage III cancer specimen, the stage IV cancer specimen had the highest amount
of nests that contained >100 lymphocytes (data not shown).

Discussion
While there have been several studies examining Bcl-2 expression with
ovarian tumor progression or the prognostic importance of the presence of
lymphocytes for clinical outcome in OC, this is the first study to examine Bcl-2
expression in both epithelial and stromal cells as well as lymphocyte distribution
with OC progression. In agreement with previous studies [57, 129, 130], I found
that over 50% of OCs stained for Bcl-2, but I also detected Bcl-2 staining in
normal and benign ovarian specimens. Further, epithelial Bcl-2 staining was
greater in normal and benign ovarian specimens compared with cancer
specimens. This is in agreement with other studies [56, 131, 132] which reported
greater Bcl-2 expression in normal and benign specimen compared to cancer
samples. Chan et al. [56] proposed that decreased Bcl-2 expression with tumor
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progression resulted from the dysregulation of Bcl-2 normally required to
maintain physiological function and integrity of the normal OSE. Similarly, other
studies [56, 129, 133] have reported an inverse relationship between epithelial
Bcl-2 expression and tumor grade. For example, Baekelandt et al. [134] found
only 39% of stage III epithelial ovarian carcinomas displayed immunoreactivity to
Bcl-2 in more than 5% of the tumor cells. They did not compare these levels to
Bcl-2 expression in normal ovarian tissue, but they did conclude that Bcl-2
expression was inversely related to tumor aggressiveness. In the present study,
57% (16/28) of the OC specimens showed positive Bcl-2 staining in more than
5% of the tumor cells regardless of cancer stage. However, when only stage III
OC specimens were considered, 42% (8/19) of the samples demonstrated
positive Bcl-2 staining in more than 5% of the tumor cells (data not shown) which
is very similar to findings reported by Baekelandt et al [134]. Interestingly, we
have recently reported increased levels of urinary Bcl-2 in OC patients ([135],
Chapter 4) suggesting that reduced epithelial Bcl-2 staining with tumor
progression may reflect a transition from cellular expression of Bcl-2 to secreted
Bcl-2 associated with disease progression.
Further, normal ovarian endocrine and reproductive function depends on a
multifaceted and dynamic microenvironment that involves coordinated cell-cell
interactions [136]. Likewise, stromal-epithelial interactions, as seen in breast
carcinomas [137-139], play an important role in determining ovarian malignant
progression. This is supported by the observation that OSE tumor cells are
closely associated with their surrounding stromal cells [140]. Interestingly,
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conditioned media from normal stromal cells inhibits proliferation of SKOV3 and
Caov3 OC cell lines in vitro [136], while nude mice co-injected with SKOV3 or
OCC1 OC cells and normal stromal cells display a slower onset of tumor
formation and rate of tumor growth compared to mice injected with cancer cells
alone [123]. Additionally, precursors of OSE tumors, such as hyper- and
metaplastic changes of the OSE and associated inclusion cysts, are related to
stromal hyperplasia [141]. In the present study, I found that stromal Bcl-2
staining decreased with malignant progression and the intensity of stromal Bcl-2
expression was inversely related to tumor grade, possibly suggesting that
alterations in stromal components might promote tumor progression. Taken
together, these findings support a role of tumor-stromal interactions in the
regulation of tumorigenesis as well as tumor progression in EOC.
Lastly, OC is a highly immunogenic disease, which triggers the influx of a
large number of lymphoid cells to the tumor site. Lymphocytes play a major role
in the host immune response since stimulated lymphocytes release cytokines,
antibodies, and growth factors necessary for immune-mediated tumor cell lysis
[142]. Consequently, the presence of T cells is generally associated with an
improved clinical outcome in advanced ovarian carcinoma. Adams et al. [143]
showed that OC patients who have tumors with a high frequency of intraepithelial
T cells, specifically CD8+ T cells, have a significantly better 5-year survival rate
than patients whose tumors have a low frequency of intraepithelial CD8+ T cells.
Likewise, Clarke et al. found that the presence of intraepithelial CD3+ and CD8+ T
cells was associated with improved survival in patients with serous ovarian
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carcinomas, but not patients with endometrioid or clear cell carcinomas [127].
These latter findings may be related to the presence of CD8+ T lymphocytes in
underlying tumor stroma correlating with vascular invasion, thereby potentiating
tumor growth in endometrioid carcinoma [125]. In the present study, I found an
increased number of lymphocyte nests with malignant transformation in ovarian
specimens and the size of lymphocytes nests also increased significantly with
tumor progression; however, I did not have any information on patient survival to
report any prognostic data. Given that lymphocytes secrete TGF-β [144] which
can promote mesenchymal cell growth [145], focal areas of lymphocytes, then,
may support growth of higher grade ovarian tumors, especially as that pertains to
ovarian epithelial cells that have undergone epithelial to mesenchymal transition
characteristic of OC progression [146]. TGF-β is also thought to have angiogenic
properties [147] which would additionally benefit tumor growth. These findings of
increased lymphoid aggregates present with OC progression are in agreement
with other cancers including lymphoma [148], breast cancer [149], and
melanoma [150]. However, whether these lymphocytes assist in the antitumor
response or promote tumor growth remains unclear since the role that they play
may very well be disease-specific.
In this pilot study, then, it appears that alterations in Bcl-2 expression and
the number of lymphocytes may be to be correlated with OC progression.
Clearly, then, further studies with additional samples are warranted since, the
combination of Bcl-2 expression and lymphocyte status may be important for
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prognostic outcome or provide useful targets for therapeutic intervention in
patients with EOC.
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CHAPTER III
LPA-MEDIATED EXTRACELLULAR BCL-2 PROMOTES ABERRANT
ANGIOGENESIS

Abstract
Angiogenesis plays an important role in OC tumor growth and metastasis.
The ovarian tumor microenvironment is comprised of tumor cells, surrounding
stroma, and a host of circulating proteins. Bcl-2, the prototypical anti-apoptotic
protein, is overexpressed in ovarian tumors and contributes to neoplastic
transformation and drug-resistant disease, resulting in poor clinical outcome.
LPA is elevated in the plasma and ascites fluid of OC patients and has been
proposed as a diagnostic tool for OC. In addition, LPA elicits anti-apoptotic
activity through upregulation of Bcl-2 in other systems. Therefore, LPA
regulation of Bcl-2 expression in OC was assessed using an in vitro cell culture
model system. IOSE 118 and OV2008, C13, and IGROV OC cells were treated
± 10µM LPA. LPA was found to increase Bcl-2 expression at the protein and
message levels using western immunoblotting, ELISA, PCR analysis and
luciferase reporter assays. Interestingly, LPA also promoted Bcl-2 secretion by
OC cells, a novel action of Bcl-2. In vitro HUVEC tube formation assays
displayed promotion of aberrant tube formation by OC-derived and recombinant
Bcl-2. Bcl-2 appeared to modulate tube formation by inhibiting HUVEC
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migration. Given that both LPA and Bcl-2 are potential targets in OC
intervention, elucidating their inter- and regulatory relationships, especially in
angiogenesis, may be of clinical importance and warrants further investigation.

Introduction
OC, often referred to as the “silent killer”, remains the number one cause
of death due to gynecologic malignancies among women in the United States.
OC is often not diagnosed until stage III or IV, when the tumor has metastasized
beyond the pelvis. Patients diagnosed with advanced stages of OC have a 5year survival rate of less than 30%, whereas patients diagnosed in early stages
have a 5-year survival rate of almost 95% [1] . Though early stages of OC are
generally asymptomatic, typical symptoms include urinary urgency, bloating, gas,
nausea, and abdominal discomfort [151]. Further, OC patients often present with
abdominal swelling due to accumulation of malignant ascites fluid in the
peritoneal cavity most likely due to intraperitoneal spread of disease. Ascites
fluid can stimulate the proliferation of OC cells [87, 152], and, thus, has
implications in the progression of OC.
As with other vascularized tumors, the vessels in ovarian tumors differ
from their normal counterparts. Tumor blood vessels demonstrate various
structural abnormalities (such as irregular diameters and blind ends) [112], in
addition to dysregulated expression of growth factors, integrins, and receptors
[106, 108, 113]. Furthermore, tumor blood vessels display marked leakiness
which contributes to extravasation of blood cells and plasma proteins as well as

50

dissemination of tumor cells associated with metastases [153-155]. The proangiogenic factor, VEGF, promotes peritoneal vessel permeability leading to
ascites development in OC. Likewise, VEGF is present at high levels in ovarian
cyst fluid [156, 157] and ascites [158] of OC patients. Other angiogenic factors
that are elevated in the ascites fluid of OC patients include bFGF [159],
endothelin-1 (ET-1) [160], interleukin-8 [161], angiogenin [159], and TGF-α and β [162]. Alternatively, ascites fluid contains high levels of anti-angiogenic factors,
specifically, fibrinogen degradation products [163] and angiostatin [164], a
product of plasminogen cleavage. Though the reason for the net anti-angiogenic
activity of ovarian ascites fluid is poorly understood, angiostatin is implicated in
the suppression of secondary tumor growth [165].
High levels of LPA are also detected in the ascites fluid and serum of OC
patients [87-89]. LPA is also known as the “ovarian cancer activating factor”, due
to its ability to stimulate the proliferation of cancer cells [88, 166]. In addition to
its growth-inducing capabilities, LPA stimulates intracellular calcium release and
tyrosine phosphorylation, including MAPK activation [88, 166]. Furthermore, LPA
plays a role in sustained angiogenesis and evasion of apoptosis. In OC cell
lines, LPA help promotes tumor growth, angiogenesis, invasion and migration
[93, 167] by transcriptional activation of VEGF. In colon cancer cells, LPA
upregulates the expression of the pro-apoptotic protein Bcl-2 while increasing
phosphorylation of the anti-apoptotic Bad protein, providing protection from
etoposide-induced apoptosis [168]. LPA also elicits anti-apoptotic activity by
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promoting expression of Bcl-2 at both mRNA and protein levels in intestinal
epithelial cells [95].
This aim examined the effect of LPA on Bcl-2 expression in human
immortalized ovarian surface epithelial cells and OC cell lines. I found that LPA
increased Bcl-2 expression in OC cell lines. Upon analysis of the conditioned
media, I observed that LPA also mediated Bcl-2 secretion from OC cell lines. I
then determined that extracellular Bcl-2 is related to aberrant endothelial tube
formation.

Materials and Methods

Cell Lines and Reagents
SV-40 large T antigen transfected OSE (IOSE 105, 114, 118, ILOW, and
IMCC3) and ovarian carcinoma cell lines (C13, CaOV3, ES-2, IGROV, OV2008,
OV-90, OVCAR5, PA-1, and SW626) were cultured in 199/MDCB 105 medium
(Sigma Aldrich®, St. Louis, MO) supplemented with 5% Fetal Bovine Serum
(FBS, SAFC Global®, St. Louis, MO) and 10µg/mL Gentamicin (GIBCO®,
Carlsbad,CA). Clonetics® Human Umbilical Vein Endothelial Cells (HUVECs)
were cultured in EGM-2 medium (both from Lonza Walkersville, Inc.,
Walkersville, MD). All cells were incubated at 37°C with 5% CO2.
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Preparation of Conditioned Media and Cell Lysates
To measure endogenous and LPA-induced levels of Bcl-2 in IOSE and
OC cell lines, conditioned media and cell lysates were collected. Cells were
plated in 150mm petri dishes at a density of 4x106 and cultured for 24h. For
measurement of endogenous Bcl-2, fresh media was added 24h after plating and
cell pellets and conditioned media were collected an additional 24h later. For
LPA treatments, 24h after plating, cells were cultured in serum-free media (0.1%
FBS 199/105 medium) overnight. Fresh serum-free media ± 10µM oleoyl-L-αLPA (Enzo Life Sciences, Plymouth Meeting, PA) was then added to the cells,
and cell pellets and conditioned media, likewise, collected an additional 24h later.
All cell pellets were lysed in CHAPS lysis buffer and conditioned media was
concentrated using Amicon Ultra Centrifugal Filter Units with a molecular weight
cutoff of 10 kDa (Millipore, Billerica, MA) according to the manufacturer’s
instructions.

Transient Transfections and Luciferase Assays
Two million IOSE 118 and OV2008 OC cells were transiently transfected
with 1μg Bcl-2 cDNA, 1.5μg full-length Bcl-2 promoter-luciferase reporter gene
(both generously provided by Dr. Christina Pratt) or 1.5μg Green Fluorescent
Protein (GFP; Lonza Walkersville, Inc., Walkersville, MD) using Amaxa®
Nucleofector® kit V and program X-005 (Lonza Walkersville, Inc., Walkersville,
MD). For samples transfected with Bcl-2 cDNA or GFP, fresh media was added
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to transfected cells 24h post-transfection. Cells and conditioned media were
collected 48h and 72h post-transfection. For cells transfected with Bcl-2
promoter, cells were treated ± 10µM LPA 24h post-transfection and lysed an
additional 24h later. Reporter gene activity was quantified with the Dual
Luciferase® Assay (Promega Corporation, Madison, WI) per manufacturer’s
instructions. Firefly luciferase activities were normalized by Renilla luciferase
activities and data expressed as the mean relative luciferase activities of triplicate
samples ± standard error (SE).

Enzyme-Linked Immunosorbant Assay
Protein from lysed cells and concentrated conditioned media (CCM) were
assayed for Bcl-2 by Bcl-2 enzyme-linked immunosorbant assay (ELISA)
(Bender Medsystems, Burlingame, CA) according to the manufacturer’s protocol.
Bcl-2 concentrations were determined by measuring sample absorbance at
450nm using the ELx800 Universal Microplate Reader (Bio-Tek Instruments, Inc.,
Winooski, VT). Bcl-2 concentrations were calculated using the absorbance of
triplicate samples and expressed as the mean ± SE.

Immunodepletion and Immunoprecipitation of CCM
To determine the amount of total protein present in conditioned media
samples, the Bio-Rad Dc Protein Assay (Bio-Rad, Hercules, CA) was used
according to manufacturer’s protocol. Immunodepletion (ID) or
immunoprecipitation (IP) of Bcl-2 from CCM was achieved using a monoclonal
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mouse anti-Bcl-2 antibody (SC-7) and Protein A/G PLUS Agarose Bead slurry
(both from Santa Cruz Biotechnology, Santa Cruz, CA) according to
manufacturer’s protocol. ID media was used in subsequent endothelial tube
assays and IP reactions analyzed via Western Blot.

Western Blot Analysis
For Western blot analyses, protein concentrations of cell lysates were
determined using the Bio-Rad Dc Protein Assay (Bio-Rad, Hercules, CA)
according to manufacturer’s instructions. Protein extracts were solubilized in
SDS gel loading buffer (60mM Tris base, 2% SDS, 10% glycerol, and 5% βmercaptoethanol). ID CCM, IP reactions, or cell lysates were electrophoresed
via 10% SDS-PAGE and transferred to Immobilon P PVDF membrane (Millipore,
Billerica, MA) by wet transfer. Membranes were blocked with 5% milk in trisbuffered saline with tween for 1h at room temperature. Membranes were then
incubated in monoclonal mouse anti-Bcl-2 antibody overnight at 4°C followed by
goat anti-mouse HRP-conjugated antibody (both from Santa Cruz Biotechnology,
Santa Cruz, CA) for 1h at room temperature. β-actin (Sigma Aldrich, St. Louis,
MO) was used as a loading control. Bands were detected with SuperSignal West
Femto Substrate and/or Pierce ECL Western Blotting Substrate (both from
Thermo Fisher Scientific, Inc., Rockford, IL) and densitometric analysis
performed using ImageQuant 5.2 image analysis software (GE Healthcare BioSciences Corp., Piscataway, NJ). Bcl-2 intensity was normalized to β-actin and
expressed as relative densitometric intensity.
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Reverse Transcriptase Polymerase Chain Reaction
To determine whether or not LPA-induced Bcl-2 upreguation was
transcription-dependent, reverse-transcriptase polymerase chain reaction (RTPCR) was performed. Briefly, total cellular RNA was collected using TRIzol
reagent (Invitrogen, Carlsbad, CA). Reverse transcription to single-strand cDNA
was performed using 1µg of total mRNA, oligo(dT), and reverse transcriptase.
Amplification of the cDNA was carried out using the GeneAmp® RNA PCR kit
(Invitrogen, Carlsbad, CA). The Bcl-2 primers used were Bcl-2 sense 5’GGTGCCACCTGTGGTCCACCTG-3’ and antisense
5’CCTATCTGGGCCACAAGTGAAG-3’, with β-actin primers Actin sense 5’GGGAATTCAAAACTGGAACGGTGAAGG-3’ and Actin antisense 5’GGAAGCTTATCAAAGTCCTCGGCCACA-3’ for an internal control. The
amplified products were separated by electrophoresis on a 10% polyacrylamide
gel, stained with 1x SYBR Green (Lonza Cologne GmbH, Germany) and
photographed with Kodak KDS1D 2.0 image analysis software.

Tube Assay
In vitro tube formation assays were used to determine whether exogenous
Bcl-2 contributes to angiogenesis. HUVECs were cultured at a density of 5x104
on a Matrigel (BD Biosciences, San Jose, CA) overlay in 24-well plates and
supplemented with OC cell CCM ± Bcl-2 ID. Alternatively, HUVECs were
cultured at a density of 15x103 on a Matrigel overlay in 96-well plates ± 10µg/mL
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recombinant human (rh) Bcl-2 (R&D Systems, Minneapolis, MN). Tube formation
was observed at 18-21h with an inverted microscope in three fields of triplicate
wells or in 6 wells of 24- and 96-well plates, respectively. Images were captured
and analyzed using the Image Pro Plus Digital Imaging System (Media
Cybernetics, Inc, Bethesda, MD). The quantity of tube-like structure formation
was determined and defined by four parameters: number of polyhedral
chambers, area of polyhedral chambers, total tube length, and number of free
tubes. Measurements were expressed as mean ± SE.

Scratch Wound Assay
In vitro scratch wound assays were used to determine whether exogenous
Bcl-2 affected HUVEC migration. HUVECs were plated in 60mm tissue culture
dishes and grown to confluency. Confluent monolayers of HUVECs were
wounded using a 1mL micropipette tip and rinsed twice with PBS. Cells were
then cultured with EGM-2 media supplemented with OV-90 cell CCM ± Bcl-2 ID.
Wound closure was monitored for up to 48h and photographed using a digital
camera. Scratch distances from eight microscopic fields in each condition were
measured at specified time points using Image Pro Plus Digital Imaging System
(Media Cybernetics, Inc, Bethesda, MD) and graphed as the mean ± SE.

Measurement of Cell Proliferation
HUVEC viability was detected using the CellTiter 96 Aqueous One
Solution Cell Proliferation Assay (Promega Corporation, Madison, WI), a
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colorimetric assay based on soluble formazan production by dehydrogenase
enzymes found in metabolically active cells. Cells were plated at 5x103 cells per
well in triplicate. Absorbance was measured at 490nm using the ELx800
Universal Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VT). Results
were expressed as the percentage of control absorbance ± SE.

Statistical Analysis
Where applicable, Student’s t test was performed for determination of
statistical significance between control and treated samples and P values are
reported in the respective figures.

Results

OC Cell Lines Express More Bcl-2 than IOSE Cell Lines
Endogenous levels of Bcl-2 were examined in a panel of 5 normal IOSE
cell lines (105, 114, 118, ILOW, and IMCC3) and 9 OC cell lines (C13, CaOV3,
ES-2, IGROV, OV2008, OV-90, OVCAR5, PA-1, and SW626). OC cell lines
displayed overall higher cellular levels of Bcl-2 (Figure 10a). The average
cellular Bcl-2 expression in the normal IOSE cells was only 62% of the cellular
Bcl-2 seen in the OC cell lines (Figure 10a, inset). Interestingly, while IOSE cell
lines from patients with a known familial history of ovarian or breast cancer
(FHIOSE: 105, 114, and 118) had secreted Bcl-2 levels more than 2-fold higher
than IOSE cell lines from patients without a known familial history of ovarian or
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Figure 10. Intracellular and extracellular Bcl-2 levels are elevated in OC cell
lines. A. Endogenous cellular Bcl-2 protein was measured in IOSE (105, 114,
118, ILOW, and IMCC3) and OC (C13, CaOV3, ES-2, IGROV, OV-90, OVCAR5,
PA-1, and SW626) cells using Bcl-2 ELISA. Results are expressed as the mean
of triplicate samples ± SE. Inset: Bcl-2 values for IOSE (normal) and OC
(cancer) cells were combined and results expressed as the mean ± SE. B. Bcl-2
was immunoprecipitated from CM of IOSE and OC cultured for 24h. IP reaction
was analyzed via SDS-PAGE and probed for Bcl-2. Results represent relative
densitometric intensity normalized to cell count upon collection of CM. Inset:
Densitometric intensity from NFHIOSE (ILOW and IMCC3; Normal) and OC
(cancer) cells were combined and results expressed as mean relative
densitometric intensity.
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breast cancer (NFHIOSE; ILOW and IMCC3) and most of the OC cell lines
(Figure 10b), the average secreted Bcl-2 of the NFHIOSE cell lines was almost
60% lower than that of the OC cell lines (Figure 10b, inset). Therefore, cellular
and secreted Bcl-2 levels were generally higher in OC cells.

Overexpression of Bcl-2 Promotes Its Secretion
To determine if secretion of Bcl-2 is exacerbated by its overexpression,
the OC cell line OV2008 was transiently transfected with full length Bcl-2 cDNA.
Transfection was confirmed by measuring cellular Bcl-2 levels via Bcl-2 ELISA
(Figure 11a). Bcl-2 cDNA elicited increases of at least 5- and 17-fold in cellular
(Figure 11a) and secreted (Figure 11b) Bcl-2, respectively, compared to cells
transfected with GFP. Additionally, cellular increases in Bcl-2 preceded the rise
of Bcl-2 secretion, suggesting that cellular Bcl-2 levels may reach a threshold,
resulting in further Bcl-2 secretion.

LPA Increases the Expression of Bcl-2
Since LPA has previously been shown to upregulate Bcl-2 in epithelial
cells [95], I assessed whether LPA increases Bcl-2 expression and/or secretion
in IOSE and OC cell lines. I found that LPA increased cellular Bcl-2 expression
(Figure 12A) and secreted Bcl-2 (Figure 12B) by up to two-fold and 10%,
respectively. Bcl-2 levels were unchanged with LPA treatment in IOSE 118 cells
(Figure 12A and 12B). Likewise, LPA amplified Bcl-2 mRNA expression by up to
9-fold in OC cell lines, while IOSE 118 mRNA levels were unchanged by LPA
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Figure 11. Bcl-2 overexpression increases cellular and extracellular Bcl-2
levels. OV2008 cells were transiently transfected with Bcl-2 cDNA. Fresh media
was added 24h post-transfection followed by collection of cell pellets and
conditioned media an additional 24 and 48h later. Cellular (A) and extracellular
(B) Bcl-2 protein was measured in duplicate samples via Bcl-2 ELISA and
expressed as mean ± SE.
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Figure 12. LPA enhances cellular and secreted Bcl-2 Levels. IOSE 118,
OV2008, C13, and IGROV cells were serum-starved overnight and treated ±
10µM LPA for 24h. A. Cell lysates were subjected to SDS-PAGE and Western
immunoblot for Bcl-2. Bcl-2 levels were normalized to β-actin. Data is graphed
as fold change in relative densitometric intensity. B. Bcl-2 protein in CCM was
analyzed by Bcl-2 ELISA and results expressed as mean of duplicate samples.
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(Figure 13A). Further, LPA did not affect IOSE 118 Bcl-2 promoter activity
(Figure 13B). It did, however, increase Bcl-2 promoter activity by more than 60%
in the OV2008 OC cells (Figure 13B). Together, these data suggest that LPAinduced Bcl-2 upregulation is transcriptionally dependent.

Extracellular Bcl-2 Affects Angiogenesis
Bcl-2 expression levels in tumor vasculature-associated endothelial cells
have been correlated with tumor angiogenesis and growth [169, 170]. However,
the effect(s) of extracellular Bcl-2 on angiogenesis has not been investigated.
Removal of Bcl-2 from OV2008 CCM via ID was verified by western blot (Figure
14A). HUVECs cultured with Bcl-2 ID CCM had almost 40% more polyhedral
chambers and produced a 25% longer tube-like network than HUVECs grown in
the presence of Bcl-2 (Figure 14B and 15). Additionally, HUVECs grown without
Bcl-2 showed 67% smaller chambers and 44% fewer free-ended tube-like
structures (Figure 15) than HUVECs grown with Bcl-2. To verify the relationship
between Bcl-2 and aberrant endothelial tube formation, tube assays were
performed with rhBcl-2. In agreement, HUVECs cultured without rhBcl-2 had
60% more polyhedral chambers than their Bcl-2 treated counterparts (Figure 16).
HUVECs cultured without rhBcl-2 also formed 20% more tube-like structures
overall and had 25% smaller chambers than the HUVECs cultured with rhBcl-2,
though these measurements did not quite reach statistical significance (Figure
16). However, in contrast to the tube assays performed with OC cell CCM,
HUVECs grown with rhBcl-2 had 15% fewer free ended tube-like structures than
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Figure 13. LPA increases Bcl-2 mRNA levels and promoter activity. A.
IOSE 118, IGROV, and OV2008 cells were serum-starved overnight and treated
± 10µM LPA for 24h and examined by RT-PCR for Bcl-2 and β-actin. PAGE
following RT-PCR revealed a 459 bp Bcl-2 product and a 98 bp Actin product.
Bcl-2 band intensities were normalized to respective actin intensities and fold
change between control and treated samples was calculated and noted below
the bands. B. IOSE 118 and OV2008 cells were transiently cotransfected with
full-length Bcl-2 promoter luciferase reporter plasmid and Renilla hRluc luciferase
reporter plasmid. Twenty-four hours post-transfection, cells were treated ± 10µM
LPA for 24h. Firefly luciferase activity was normalized to Renilla luciferase
activity and expressed as mean relative luciferase activity ± SE for triplicate
samples.
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Figure 14. Bcl-2 promotes aberrant endothelial tube formation. A. Bcl-2
was immunoprecipitated from OV2008 CCM. IP reaction (control) and
supernatant (Bcl-2 ID) were analyzed via SDS-PAGE by probing with Bcl-2.
Supernatant was saved for subsequent endothelial tube assays. B.
Representative photograph (40X magnification) of Matrigel tube formation assay
in which HUVECs were cultured with OV2008 CCM ± Bcl-2 ID for 18-21h.
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Figure 15. Differences in angiogenesis parameters ± OC cell-derived Bcl-2.
Following endothelial tube formation assays, angiogenesis parameters were
quantified in three fields of triplicate wells for each condition and graphed as
mean measurements ± SE.
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Figure 16. Differences in angiogenesis parameters ± rhBcl-2. Following
endothelial tube formation assays, angiogenesis parameters were quantified in
three fields of triplicate wells for each condition and graphed as mean
measurements ± SE.

67

controls, though this difference did not reach statistical significance (Figure 16).
Collectively, these findings suggest that extracellular Bcl-2 may play a role in
angiogenesis, specifically promoting aberrant tube formation.

Extracellular Bcl-2 Reduces Endothelial Cell Migration
To begin to understand the mechanisms by which exogenous Bcl-2 can
promote aberrant tube formation, in vitro wound assays and MTS assays were
performed to assess endothelial cell migration and cell proliferation, respectively.
HUVECs cultured without Bcl-2 migrated approximately 15% faster than
HUVECs cultured in the presence of Bcl-2 at both 24 and 30h (Figure 17A). The
statistical difference in migration at 24h is noteworthy because this coincides with
the time that tube formation was quantified. In contrast, addition of rhBcl-2 did
not significantly affect HUVEC viability (Figure 17B). These initial studies,
therefore, suggest that exogenous Bcl-2 may promote aberrant tube formation by
inhibiting endothelial cell migration.

Discussion
Bcl-2 was originally identified as the deregulated oncoprotein associated
with the t(14:18) chromosome translocations commonly found in B-cell
lymphomas [37, 171]. Bcl-2 is the founding member of the Bcl-2 family of
proteins involved in regulation of apoptosis. The family consists of anti-apoptotic
(e.g. Bcl-2, Mcl-1, Bcl-XL) and pro-apoptotic members (e.g. Bax, Bad, Bim). The
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Figure 17. Bcl-2 reduces HUVEC migration but not cell viability. A.
Confluent monolayers of HUVECs were wounded with a micropipette tip and
cultured with OV-90 CCM ± Bcl-2 ID. Scratch distances from eight microscopic
fields were measured at 0, 6, 24, and 30h and graphed as mean distance ± SE.
B. HUVECs were cultured ± rhBcl-2 and cell viability was measured by MTS at 0
and 24h following treatment. Cell viability from triplicate samples is expressed as
percentage of control ± SE.
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pro-apoptotic Bcl-2 family members homodimerize, causing permeabilization of
the outer mitochondrial membrane and release of cytochrome C which leads to
caspase activation and, ultimately, apoptosis. The anti-apoptotic family members
function to secure the outer mitochondrial membrane’s integrity by forming
heterodimers with the pro-apoptotic family members thereby directly inhibiting
their apoptotic activity [42]. Bcl-2 is the prototypic anti-apoptotic Bcl-2 family
member and is elevated in a number of solid tumors, including ovarian
carcinomas [172].
Currently, I confirmed that Bcl-2 levels were significantly higher in OC cell
lines compared to normal IOSE cell lines. I also found that both OC and IOSE
cells secrete Bcl-2. Of interest, IOSE from patients with a familial history of
ovarian or breast cancer secreted higher levels of Bcl-2. Studies correlating Bcl2 expression with familial history of cancer are few and contradictory. Bauer, et
al. found that Bcl-2 did not significantly correlate to a positive familial history in
patients with prostate cancer [173]. Similarly, Bcl-2 expression did not differ
between sporadic and hereditary medullary thyroid carcinomas [174]. On the
other hand, Piek et al. [175], observed higher Bcl-2 levels in surface and
inclusion cyst epithelium of prophylactically removed ovaries from women with a
hereditary predisposition for female adnexal cancer. While Bcl-2 is expressed at
lower levels in patients with BRCA1-associated breast cancers [176, 177], we
recently found that women with a familial history of breast or OC have elevated
urinary Bcl-2 ([135], Chapter 4). Both Bcl-2 and Bcl-x expression were increased
in patients with hereditary leiomyomatosis and renal cell carcinoma, however,
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Bak expression was decreased in these patients [178]. Additionally, loss of Bax
expression is associated with hereditary non-polyposis colorectal cancer [179,
180]. Different alterations in apoptotic machinery, then, may specifically
contribute to some sporadic and hereditary cancers.
Given that Bcl-2 is generally described as an intracellular protein localized
to the outer mitochondrial membrane, ER, or perinuclear membrane [43, 44], in
vitro secretion of Bcl-2 reported herein is novel. Though serum Bcl-2 levels have
been evaluated in a variety of illnesses [181-186] and the cerebral spinal fluid of
patients with traumatic brain injury [187, 188], there are limited studies on the
effects of extracellular Bcl-2 both in vivo and in vitro. In mice, exogenously
administered rhBcl-2 or rhBcl-2A1 were able to protect hind limb skeletal muscle
or cardiac muscle from ischemia-reperfusion injury [189], leading Iwata et al. to
suggest that Bcl-2, Bcl-2A1, and BH4-domain peptides are among an enlarging
group of danger-associated molecular patterns (DAMPs). DAMPs or ‘alarmins’
are intracellular constituents that act extracellularly to engage receptors on
immune or adjacent cells and facilitate activation of the innate immune system.
Iwata’s group deduced that the cytoprotective effect of Bcl-2, Bcl-2A1, and their
BH4 peptides was mediated via toll-like receptor 2 (TLR2) signaling through a
MyD88-dependent pathway. Perhaps, then, secreted Bcl-2 in ovarian systems
may likewise enhance immune response and result in increased presence of
lymphocytes as noted with OC progression in chapter 2.
This study is not the first to observe extra-apoptotic Bcl-2 functions.
However, this is the first report of aberrant tube formation associated with
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extracellular Bcl-2. Interestingly, Bcl-2 has been shown to influence axonal
elongation and outgrowth [190-192]. Ureteric bud cells lacking intracellular Bcl-2
demonstrated: 1) faster cell migration; 2) increased invasion; 3) decreased
thrombospondin-1 and osteopontin expression; 4) increased expression of α1and α2-integrin subunits; and 5) increased fibronectin expression [193] compared
to those expressing Bcl-2. Though these experiments dealt with the effects of
intracellular Bcl-2, my findings are similar such that removal of extracellular Bcl-2
increased endothelial cell migration. Overexpression of Bcl-2 in mammary
epithelial cells promoted multilayering of cells and formation of three-dimensional
structures at confluence. Bcl-2 also facilitated the formation of branching
structures in collagen gels, suggesting that Bcl-2 may assist in differentiation in
the mammary gland [194]. Additionally, in mammary epithelial cells, Bcl-2
overexpression did not promote tumorigenesis. In contrast, endothelial cells
cultured without Bcl-2 had a higher propensity for tube-like structure formation
compared to the aforementioned studies [193, 194] which observed increased
tube-like structures in ureteric bud and mammary epithelial cells with Bcl-2. The
differences between the morphogenetic properties of Bcl-2 could be due to the
distinct cell types or signaling pathways activated by extracellular Bcl-2. For
instance, Segura, et al., found that overexpression of Bcl-2 in HUVEC resulted in
impaired vessel-like structure formation in vitro and that pharmacological
inhibition of apoptosis, using caspase inhibitors, blocked VEGF-dependent
vascular formation in vivo [107]. Likewise, cell viability did not influence Bcl-2mediated decreases in vessel-like tube formation in the present study. Since
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extracellular Bcl-2 maintains its anti-apoptotic activity [189], the current findings
support the theory that early stages of angiogenesis require apoptosis for proper
vascular network formation. This is further supported by studies showing that
apoptosis is needed for proper remodeling [195] and lumen formation [196]
involved in angiogenesis.
Lastly, secretion of Bcl-2 was enhanced by LPA in this study. It is well
known that LPA is elevated in serum and ascites fluid of OC patients [87, 88]
and, thus, has been considered as a biomarker for OC [89]. LPA stimulates
VEGF expression in OC cell lines [93], indirectly stimulating ovarian tumor
growth, in part, by increasing angiogenesis via VEGF. Our group has previously
shown that LPA may also promote OC cell survival through VEGF-mediated
upregulation in telomerase activity [197]. Further, in addition to its proangiogenic activity, VEGF also aids in endothelial cell survival by upregulating
anti-apoptotic proteins Bcl-2 and Bcl-2A1 [198]. Though the current study did not
determine whether LPA-mediated Bcl-2 secretion was VEGF-dependent, the
findings herein suggest that tumor-secreted Bcl-2 may be yet another component
of a paracrine loop between ovarian tumor and endothelial cells involved in
modulation of angiogenesis.
In conclusion, Bcl-2 may play a dual role in tumorigenesis, through its antiapoptotic function, which promotes tumor cell growth and confers
chemoresistance, and by contributing to abnormal formation of tumor
vasculature. In the latter context, it is tempting to speculate that extracellular Bcl2 could promote abnormal vessel structure in ovarian tumors by altering
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endothelial cell migration and remodeling, ultimately contributing to drug
resistance by limiting therapeutic access to tumor cells. Finally, further studies
on the mechanism(s) of extracellular Bcl-2 function are warranted given its
potential as a target for therapeutic intervention.
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CHAPTER IV:
URINARY LEVELS OF BCL-2 ARE ELEVATED IN OVARIAN CANCER
PATIENTS

Abstract
The poor prognosis associated with OC is due to the lack of overt early
symptoms and the absence of reliable diagnostic screening methods. Since
many tumors overexpress anti-apoptotic proteins, the purpose of this study was
to determine whether elevated levels of the anti-apoptotic protein Bcl-2 were
present in urine from patients with OC. Bcl-2 was assayed by ELISA in urine
samples from two cohorts consisting of a total of 77 healthy women, 161 women
with benign gynecologic disease and 150 women with OC, 13 with early and 137
with late stage disease, respectively. Wherever possible, parallel serum samples
were measured for CA125 levels by ELISA. Urinary levels of Bcl-2 from healthy
individuals or women with benign disease averaged 0.59 ng/ml ± 0.61 and 1.12
ng/ml ± 0.79, respectively. In contrast, urinary levels of Bcl-2 averaged 2.60
ng/ml ± 2.23 and 3.58 ng/ml ± 1.55 from women with early (N=13) and late
(N=137) stage OC. Further, urinary levels of Bcl-2 were elevated in OC patients
regardless of tumor grade, stage, size, histologic subtype, creatinine levels or
patient age, but appeared to complement CA125 measurements. Levels of Bcl-2
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are elevated in the urine of patients with OC and may be of diagnostic and/or
prognostic clinical importance. Further studies of urinary Bcl-2 as a biomarker for
OC alone or in combination with other markers are warranted.

Introduction
OC is the fifth leading cause of cancer death among women after lung,
breast and colorectal cancer and is associated with a 1.7% lifetime risk [199].
The lack of early, overt symptoms and the absence of a reliable screening test
result in over 70% of women being diagnosed after the disease has spread
beyond the ovary so that the prognosis is poor (5-year survival is no better than
37%). For women at high risk for developing OC, annual pelvic examination,
transvaginal ultrasound, and/or measuring blood levels for CA125 are the
generally recommended screening methods available for detection of OC.
However, use of these techniques for screening purposes is limited [200].
To safely and economically detect cancer with no or minimal invasiveness,
previous studies have examined biological fluids for detectable cancer
biomarkers. These include examining serum levels of soluble interleukin-2 as a
marker for hematological malignancies [201], prostate-specific antigen and
insulin-like growth factor binding protein-3 in nipple aspirate fluid from breast
cancer patients [202] and urine levels of angiostatin and plasminogen or survivin
for the detection of bladder cancer and sarcoma, respectively [203, 204]. In the
ovary, in addition to elevated serum CA125, LPA is also found in high levels in
plasma and ascites of OC patients and is considered a potential diagnostic
76

marker for OC [205]. Likewise, Hazelton et al [157] showed high levels of VEGF
in cysts from OCs compared to cystic fluid from benign, borderline or functional
cysts. However, the invasive nature for cystic fluid collection prohibits widespread
use for general screening/diagnostic purposes. Strategies using multiple serum
markers may increase sensitivity for OC detection, but have yet to provide useful
and cost-effective screening [206]. Proteomic analysis can distinguish OC sera
from those of healthy women. Individual proteomic biomarkers still require
validation and the use of protein profiles has been hampered by the difficulties in
defining optimal algorithms and inter-assay variability [207]. Recently, elevated
serum and urinary levels of mesothelin have also been associated with OC [208].
Deregulation of apoptosis due to overexpression of anti-apoptotic proteins
contributes to the malignant phenotype by supporting cancer cell growth and
therapeutic resistance. Since the anti-apoptotic protein, Bcl-2, is overexpressed
in OCs [59] and secreted by OC cells in culture (Chapter 3), I sought to assess
whether elevated urinary levels of Bcl-2 are associated with OC.

Methods and Materials:

Patient cohort
With prior institutional approval, urine and blood samples were collected
from an initial cohort of healthy controls (N=19), women with benign gynecologic
disorders (N=38) and patients with early (eOC, N=4) and late (lOC, N=31) stage
OC at the H. Lee Moffitt Cancer Center at the University of South Florida (USF).
All except 8 specimens were collected prior to initial surgical cytoreduction while
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the latter 8 specimens presented with recurrent disease at the time of enrollment
in this study. The cancer category consisted of women diagnosed with OC and
primary peritoneal cancer, which is often related to OC. The samples collected
from women with benign gynecologic disease consisted of broad range of nonmalignant gynecologic disorders. The second blinded urine sample cohort
collected with IRB approval through the tissue bank at the M.D. Anderson Cancer
Center (MDA) consisted likewise of healthy controls (N=58), women with benign
gynecologic disease (N=123) and women with eOC (N=9) and lOC (N=106).
Though these cohorts comprise a small pilot study (Table 4), they are
representative of a typical clinical practice with regards to histology, grade and
stage distribution.
Paraffin blocks were identified, where possible, and the slides reviewed to
confirm the histologic diagnosis according to FIGO scores. Annonymized
information regarding patient age, tumor type, stage, grade, size and CA125
values was also obtained as per availability.

Sample Preparation
Urine and blood samples were collected from patients, annonymized, and
decoded to protect patient identity, and released from the tissue banks for this
research project. All samples were kept in ice following collection. USF urine
samples were treated with a standard protease inhibitor cocktail (80 µg/ml 4-(2
aminoethyl)-benzene sulfonyl fluoride, 200 µg/ml EDTA, 0.2 µg/ml leupeptin, 0.2
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TABLE 4. Histologic diagnoses and clinical characteristics of the study
population.
Years (mean ± SD; range)

Sample Number

54.49 ± 12.7; 29-81
55.90 ± 13.9; 28-84

n=19
n=38
10
10
9
4
2
2
1
n=35

USF Cohort
Normal
Benign
Cysts
Serous Cystadenoma
Leiomyoma
Adenofibroma
Mucinous Cystadenoma
Teratoma
Polycystic Disease
Ovarian Cancer
Histotype:
Endometrioid
Mucinous
Peritoneal
Serous
Stage
I
II
III
IV
Grade
1
2
3

MDA Cohort
Normal
Benign
Cysts
Serous Cystadenoma
LMP
High Risk
Leiomyoma
Teratoma
Endometriosis
Serous Cystadenofibroma
Fibroma
Endometrial Hyperplasia
Mucinous Cystadenoma
Adenomyosis
Brenner Tumor
Ovarian Cancer
Histotype
Serous
Endometrioid
Mucinous
Granulosa
Stage
I
II
III
IV

66.21 ± 13.8; 26-92

1
7
2
25
3
1
23
8
8
10
17

63.31 ±6.56; 51-77
49.48 ± 14.19; 19-81

n=58
n=123
31
19
14
13
12
11
8
4
3
3
2
2
1

60.51 ± 12.27; 33-88

n=115
99
12
3
1
6
3
90
16
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µg/ml pepstatin, Sigma Scientific, St. Louis, MI) and centrifuged at 3000 x g.
Urinary supernates and plasma samples were then aliquoted and stored at 20oC. Urine samples from MDA were likewise centrifuged, but without addition of
protease inhibitors and the supernatants aliquoted and frozen at -80oC.

Bcl-2 ELISA
To measure Bcl-2 levels in patients’ urine, samples were assayed using a
quantitative sandwich Bcl-2 ELISA (Bender MedSystems, Burlingame, CA)
according to the manufacturer’s instructions. In accordance with previous studies
[208], urinary Bcl-2 threshold levels were set to include 95% of Bcl-2 values of
urine samples from healthy women. When not derived from clinical data, CA125
levels in subjects’ plasma were assayed by ELISA (Bio-Quant, San Diego, CA)
according to the manufacturer’s instructions. The enzymatic reactions were
detected at 450 nm using a Dynex MRX plate reader (Dynex Technologies,
Chantilly, VA) and Bcl-2 results expressed as the mean absorbance of triplicate
samples ± SE, while CA125 results were expressed as the mean of duplicate
samples.

Statistical Analysis
Samples for Bcl-2 ELISA were run in triplicate and the data subjected to
descriptive, one way ANOVA, Tukey and ROC-AUC analyses.

80

Results

Urinary Levels of Bcl-2 are Elevated in Patients with OC from the USF Cohort
Since a standard cutoff threshold value for urinary Bcl-2 has not been
established, I used the 95th percentile of Bcl-2 values for healthy controls as the
threshold as previously employed to determine threshold values for urinary
mesothelin [208]. The amount of urinary Bcl-2 was generally negligible (average
0.30 ng/ml) in healthy control samples (Fig. 18A, Table 5) with no samples above
the determined threshold of 1.7856 ng/ml. Similarly, urinary Bcl-2 levels from
women with benign gynecologic disease were low averaging 0.74 ng/ml (Fig.
18B, Table 5). In contrast, urinary Bcl-2 associated with ovarian and primary
peritoneal cancer was generally >10x that found in normal control. Interestingly,
only two OC samples exhibited Bcl-2 levels below the threshold level (1.12 ng/ml
and 1.78 ng/ml), but it is noteworthy that these samples were derived from
patients with mucinous OC. Further of note, a single benign sample and a single
OC sample patient demonstrated extremely elevated urinary Bcl-2 levels in the
absence of other notable clinical symptoms. Since these two extreme values
were greater than the mean + 2.58 SD, they were omitted from the summarial
box plots (Fig. 19A). Because ANOVA tests revealed significant differences
among the four ovarian samples (F value = 64.48, p<0.001), pair-wise
comparisons were used in further Tukey analyses (Table 6). These latter
analyses indicated significant differences in urinary Bcl-2 between healthy
controls and benign samples, between healthy controls and cancer samples as
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Figure 18. Urinary Bcl-2 levels are elevated in OC patients. As representative, urinary samples are shown from the
USF cohort examined by ELISA for Bcl-2 levels in normal healthy controls and OC patients (A) and in benign samples (B).
Samples were examined in triplicate and the data expressed as the average ng/ml of Bcl-2 ± SE. Cancer samples were
subdivided into histologic subtype: endometrial (white bars), mucinous (striped bars), primary peritoneal (checkered bars)
and serous carcinomas (grey bars) and the latter further subdivided by tumor grade. Urinary sample #41 from an OC
patient was included in (B) to serve as a positive control
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TABLE 5. Elevated urinary Bcl-2 in cohorts as descriptive statistical
information.
Type

#

Mean

SD

Median

Min

Max

USF
Normal
Benign
eOC
lOC

19
38
4
31

0.30
0.74
2.38
2.54

0.39
0.66
0.75
1.83

0.15
0.68
2.10
3.17

0
0.10
1.86
1.12

1.26
3.99
3.48
9.80

MDA
Normal
Benign
eOC
lOC

58
123
9
106

0.69
1.23
2.70
2.30

0.64
0.79
2.68
1.34

0.57
1.20
1.94
1.94

0
0
1.05
0

2.55
3.82
9.65
8.78

USF + MDA
Normal
Benign
eOC
lOC

77
161
13
137

0.59
1.12
2.60
3.58

0.61
0.79
2.23
1.55

0.39
1.05
1.96
2.13

0
0
1.05
0

2.55
4.00
9.65
9.80
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Figure 19. Urinary Bcl-2 levels are elevated in OC patients. Urinary samples
from the USF (A), MDA (B) and combined USF + MDA (C) cohorts were
examined by ELISA for Bcl-2 levels in normal healthy controls, women with
benign disease and early and late stage OC patients. Samples were examined in
triplicate, the data expressed as the average ng/ml of Bcl-2 ± SD and graphed as
box plots.
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TABLE 6. Elevation of urinary Bcl-2 from healthy women and from patients with benign lesions, early (eOC) and
late (lOC) stage ovarian cancer.
ROC-AUC

95%

Tukey Mean Difference

USF
Normal vs. Benign
Normal vs. All Cancer
Normal vs. eOC
Normal vs. lOC
Benign vs. All Cancer
Benign vs. eOC
Benign vs. lOC
eOC vs. lOC

83%
100%
100%
100%
ND
ND
ND
ND

15.8%
100%
100%
100%
ND
ND
ND
ND

0.3586
2.9193
2.0829
3.0308
2.5607
1.7243
2.6722
0.9478

0.4568
2.2938
0.4936
2.1838
2.0419
0.2037
1.9624
-0.58898

1.17*
3.55*
3.67*
3.88*
3.08*
3.24*
3.38*
2.48

MDA
Normal vs. Benign
Normal vs. All Cancer
Normal vs. eOC
Normal vs. lOC
Benign vs. All Cancer
Benign vs. eOC
Benign vs. lOC
eOC vs. Loc

71%
90%
90%
90%
ND
ND
ND
ND

17.9%
50.4%
44.4%
50.9%
ND
ND
ND
ND

0.5425
1.5219
1.1355
1.5513
0.9794
0.593
1.0088
0.4158

0.1608
1.1686
0.2316
1.1592
0.6944
-0.2815
0.6904
-0.4632

0.92*
1.87*
2.04*
1.94*
1.26*
1.47
1.33*
1.29

USF + MDA
Normal vs. Benign
Normal vs. All Cancer
Normal vs. eOC
Normal vs. lOC
Benign vs. All Cancer
Benign vs. eOC
Benign vs. lOC
eOC vs. lOC

71%
93%
92%
93%
ND
ND
ND
ND

17.39%
76.67%
66.23%
77.37%
ND
ND
ND
ND

0.5061
1.8512
1.4172
1.8897
1.3451
0.9111
1.3837
0.4725

0.0834
1.5286
0.4714
1.4545
1.0831
-0.001
1.0275
-0.4455

0.93*
2.17*
2.36*
2.32*
1.61*
1.82
1.74*
1.39

ND, not determined; *p<0.01
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95% CI

well as between benign samples and cancer samples. ROC-AUC analyses
indicated that every cancer sample (both eOC and lOC) were above the
threshold (Table 6). Lastly, I did not detect any significant change in urinary Bcl-2
levels when representative samples were tested following repeated freeze thaws
(up to 3 times), following storage at -20o or -80o C (> 3 months for each
temperature) or at 4oC for one week (data not shown).

Urinary Levels of Bcl-2 are Elevated in OC Patients from the MDA Cohort
For validation purposes, urinary Bcl-2 levels were measured in a second
sample cohort obtained from MDA. In agreement with the USF cohort, urinary
Bcl-2 was low in healthy control or benign samples (average 0.69 ng/ml and 1.23
ng/ml, respectively) (Table 5). Urinary Bcl-2 associated with OC was elevated
and averaged 2.70 ng/ml and 2.30 ng/ml from eOC and lOC, respectively. In
contrast to the USF cohort, however, some eOC and lOC samples fell below the
determined threshold and may reflect differences in the cohorts especially as that
may pertain to sample preparation and storage. Also as above, since a single
eOC and lOC sample demonstrated extreme values were greater than the mean
+ 2.58 SD, they were omitted from the summarial box plots (Fig. 19B). Because
ANOVA tests revealed significant differences among the four ovarian samples (F
value = 40.84, p<0.001), pair-wise comparisons were used in further Tukey
analyses (Table 6). These latter analyses indicated significant differences in
urinary Bcl-2 between healthy controls and benign samples and between healthy
controls and cancer samples. While benign samples tended to be lower than

86

eOC, they were not statistically significant and there were no differences
between eOC and lOC. ROC-AUC analyses also indicated that over 50% of
cancer samples were above the threshold (Table 6).
When the data from both USF and MDA cohorts was combined (Fig. 19C,
Tables 5 & 6), urinary Bcl-2 levels in OC remained elevated. That is, urinary Bcl2 levels among healthy and benign samples (averages 0.59 ng/ml and 1.12
ng/ml, respectively) were statistically lower than those from eOC and lOC
(averages 2.60 ng/ml and 3.58 ng/ml, respectively).

Surgical Debulking Reduces Urinary Levels of Bcl-2
Levels of urinary Bcl-2 were compared in 7 OC patients immediately prior
to (Fig. 20, black bars) and within 2 weeks following initial cytoreductive surgery
(Fig. 20, white bars). Though this subset represents a small sample size, Bcl-2
levels decreased up to 100% following surgical removal of tumor further
suggesting that presence of tumor correlates with elevated urinary Bcl-2 in OC
patients.

Patients at High Risk for OC May be Predisposed to Elevated Urinary Levels of
Bcl-2.
Though there was a tendency for elevated Bcl-2 levels with increasing
tumor grade and stage, the differences were not statistically significant (Tables 5
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Figure 20. Urinary Bcl-2 decreases after cytoreductive surgery. Urinary levels of Bcl-2 were measured in duplicate
by ELISA from seven patients of the USF cohort prior to initial surgery (black bars) and within 2 weeks following their
initial cytoreductive surgery (white bars). The data are expressed as the mean ng/ml Bcl-2.
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& 6). Likewise, urinary Bcl-2 levels did not appear to vary between cancer
histotypes and serum creatinine measured at the time of urine collection
indicated that elevated urinary Bcl-2 levels in cancer patients were not related to
renal dysfunction (data not shown). In addition, while elevated levels of Bcl-2
could be detected in the serum of some OC patients (data not shown), serum
levels of Bcl-2 did not detect OC as accurately as urinary levels of Bcl-2 perhaps
due to the presence of confounding proteins in serum compared to urine.
Further, comparison of clinical parameters also indicated that urinary Bcl-2 levels
did not relate with patient age (data not shown). Though the overall average age
from normal controls and benign samples were somewhat less than that from OC
patients (Table 4), the age range among all samples was comparable. Similarly,
urinary Bcl-2 levels did not correlate with tumor size measured at cytoreductive
surgery (data not shown) and may reflect variation in tumor composition.
However, initial analyses of benign gynecologic samples from the MDA cohort
revealed a subset of 10 individuals with elevated urinary Bcl-2 above threshold
levels (Fig. 21). Upon further examination, 8 of these were identified as
individuals at risk of developing OC due to a familial history of breast and/or OC,
previous treatment for breast cancer or BRCA mutations carriers.

Urinary Bcl-2 Complements CA125 Measurements
To address the potential for urinary Bcl-2 to serve as a biomarker for OC,
urinary Bcl-2 was compared with CA125 values. Using 12 healthy controls and
23 patients with OC from the USF cohort (Fig. 22), elevated urinary Bcl-2
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Figure 21. Patients at high risk may demonstrate elevated urinary Bcl-2
levels. Urinary samples from the MDA cohorts were examined by ELISA for Bcl2 levels in normal healthy controls or in individuals at high risk for OC and plotted
as a scatter plot.
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Figure 22. Urinary Bcl-2 complements CA125. Wherever possible, urinary levels of Bcl-2 expressed as ng/ml ± SE.
(A) and blood levels of CA125 expressed as average U/ml (B) were measured by ELISA from the same healthy controls
and OC patients (muc, mucinous; PP, primary peritoneal; serous, serous adenocarcinoma) prior to initial cytoreductive
surgery from the USF cohort. White bars indicate Bcl-2 levels < 1.8 ng/ml (A) and CA125 levels < 35 U/ml (B) while *
indicates CA125 levels > 600 U/ml.
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(>1.8ng/ml) was associated with 95% OC detection (Fig. 22A) correctly
identifying 17/17 patients with serous adenocarcinoma, 4/4 patients with
mucinous OC and 1/2 patients with primary peritoneal cancer as OC positive.
None of the healthy controls had urinary Bcl-2 levels >1.8 ng/ml and were, then,
correctly classified as cancer-negative. In contrast, CA125 levels >35 U/ml from
matched samples identified 13/17 or 76% of patients with serous
adenocarcinoma, 3/4 or 75% of patients with mucinous OC (though CA125 levels
in these patients ranged between 41-43 U/ml somewhat above threshold CA125
values), and 1/2 or 50% of patients with primary peritoneal cancer as cancer
positive, while 2/12 or 16% of healthy controls were false positive (Fig. 22B).
When urinary Bcl-2 levels were compared with CA125 values among eOC
(N=17) and lOC (N=83) cancers collected from both USF and MDA cohorts, high
urinary Bcl-2 was detected in 5 (29%) early and 60 (72%) late OCs compared
with 13 (76%) and 76 (92%) CA125 measurements. However, combined urinary
Bcl-2 and CA125 positivity in these groups increased to 14 (82%) and 82 (99%)
detection of early and late cancer, respectively. In addition, comparison between
urinary Bcl-2 and CA125 measurements revealed a Pearson correlation of 0.644,
p<0.0001 indicative of strong complementarity.
Interestingly, 7/8 samples collected from women with endometriosis, often
a cause for false positive CA125 values, tested negative for urinary Bcl-2 while
the remaining sample tested just at, but not above, the threshold level for urinary
Bcl-2 (data not shown).
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Discussion
While apoptosis is an essential biological process for normal development
and maintenance of tissue homeostasis, it is also involved in a number of
pathologic conditions including tissue injury, degenerative diseases,
immunological diseases and cancer [209]. Whether activated by membrane
bound death receptors [210] or by stress-induced mitochondrial perturbation with
subsequent cytochrome c release [211], activation of downstream caspases
leads to stepwise cellular destruction by disrupting the cytoskeleton, shutting
down DNA replication and repair, degrading chromosomal DNA, and, finally,
disintegrating the cell into apoptotic bodies [212]. The key regulators of apoptosis
include members of the bcl-2 protein family [213].
The bcl-2 protein family consists of both pro- and anti-apoptotic protein
family members that act at different levels of the apoptotic cascade to regulate
apoptosis. The bcl-2 family members contain at least one Bcl-2-homology (BH)
domain [213]. Though all bcl-2 family members demonstrate membrane channel
forming activity, Bcl-2 (the archetypal bcl-2 family member) channels are cation
(Ca++) selective and, owing to its ER and mitochondrial membrane localization
[214], the anti-apoptotic function of Bcl-2 is at least partly mediated by its ability
to prevent calcium release from the ER and subsequent mitochondrial membrane
perturbation and cytochrome c release. Since Bcl-2 is overexpressed in many
tumor types including OC [59, 215], it contributes to chemoresistance by
stabilizing the mitochondrial membrane against apoptotic insults. Currently,
preclinical studies focused on the development of agents to inhibit Bcl-2 include
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antisense oligonucleotides such as G3,139 [216] and small molecular inhibitors
of Bcl-2 [217].
In addition to promoting cancer cell survival by promoting resistance to
apoptosis, recent studies indicate that Bcl-2 overexpression may also promote
cancer cell survival through increased angiogenesis by upregulating VEGF
expression [169]. Specifically, Bcl-2 mediates VEGF transcription in a Hif-1dependent manner and enhances VEGF mRNA stabilization [218].
Consequently, targeting Bcl-2 for therapeutic intervention may also complement
anti-angiogenic therapies.
In contrast to therapeutic targeting, my data suggest that Bcl-2
overexpression may result in increased levels of Bcl-2 in bodily fluids that could
represent a novel biomarker for OC. Specifically, data from two separate cohorts
indicated significantly elevated urinary Bcl-2 among OC patients compared to
healthy controls or women with benign gynecologic disease. While minor
differences existed between urinary Bcl-2 levels in the two cohorts examined,
these may reflect differences in cohort size, differences in initial sample storage
temperatures, length of sample storage, number of repeated freeze thaws or
necessity for addition of protease inhibitors for sample testing. However, the
similarity of Bcl-2 values among samples in both cohorts (e.g. USF healthy 0.30
ng/ml & MDA healthy 0.69 ng/ml or USF cancer 2.54 ng/ml and MDA cancer 2.30
ng/ml) appears to validate my hypothesis. Interestingly, though the number of
samples available from eOC was small, the lack of statistical differences in
urinary Bcl-2 levels between eOC and lOC suggests that urinary Bcl-2 may be
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useful for early detection of OC. Further, the most apparent clinical features
related to elevated urinary Bcl-2 are high risk for disease and complementarity
with CA125. While the former represents an important target group, the latter
suggests potentially important diagnostic and prognostic roles for urinary Bcl-2.
By helping to discern between OC and false positive CA125 values arising from
other conditions, urinary Bcl-2 measurements may improve detection of early
stage OC. Given the only association between urinary Bcl-2 and cancer reported
to date describes the presence of methylated urinary Bcl-2 DNA in urine
sediments associated with bladder cancer [219, 220], development of urinary
Bcl-2 protein testing could provide a convenient and non-invasive strategy for
detection/screening of OC. Clearly, further studies are warranted to verify the
potential for urinary levels of Bcl-2 to serve as a biomarker alone or in
combination with other markers, especially as that may pertain to screening for
OC.
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CHAPTER V:
CONCLUDING REMARKS

OC is the leading cause of gynecologic cancer-related deaths in the
United States [1]. OC is usually asymptomatic and currently lacks a routine
screening available to the general public. Therefore, an alarming number of OC
patients are diagnosed once the disease has reached advanced stages, leading
to challenges in treatment and, ultimately, poor prognoses [7]. Bcl-2
overexpression is often seen in OC patients and it has been suggested that this
protein contributes to neoplastic growth by its ability to inhibit apoptosis [48].
Therefore, it is of importance to further investigate the mechanisms provoking
overexpression of Bcl-2 in OC and the extra-anti-apoptotic roles that it may be
playing in this disease.
This study (Chapter 2) began by characterizing the correlation between
Bcl-2 expression and OC progression. Immunohistochemistry revealed
differential cytoplasmic Bcl-2 expression among tissue specimens from healthy
volunteers, patients with various benign gynecologic diseases, and OC patients.
Expression levels of both epithelial and stromal Bcl-2 decreased in extent and
intensity with OC progression. These findings are in agreement with previous
studies [56, 131, 132], suggesting that Bcl-2 is present and important in the
earlier stages of ovarian carcinogenesis. Notably, Bcl-2 can undergo
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modifications resulting in enhanced anti-apoptotic activity (i.e. phosphorylation)
[221, 222], or formation of a proteolytic pro-apoptotic fragment (i.e. caspase 3
cleavage) [223]. While one could speculate that decreases seen in tissue Bcl-2
expression with OC progression in the present study arose by Bcl-2 undergoing
one of the aforementioned posttranslational modifications, an alternative
explanation tested in chapter 3 is that Bcl-2 was secreted by OC cells.
Additionally, my immunohistochemical studies showed increased lymphocyte
infiltration with OC progression, which may represent yet another extra antiapoptotic function of Bcl-2 besides contributing to aberrant angiogenesis
(Chapter 3).
This study (Chapter 3) also investigated the mechanism by which Bcl-2 is
overexpressed in OC and found that LPA significantly upregulates Bcl-2 in OC
cell lines. Additionally, further experimentation led to the novel finding that LPA
increases secretion of Bcl-2 from OC cell lines. This is especially interesting
because our lab has previously shown that LPA mediates upregulation of
telomerase in a VEGF-dependent manner [197]. Because ovarian tumors
frequently metastasize to the omentum, and myofibroblasts play important roles
during cancer progression and metastasis [224-226], it is of interest to note that
LPA from cancer cells stimulates differentiation of human adipose tissue-derived
mesenchymal stem cells to myofibroblast cells [227] as well as their secretion of
VEGF and stromal cell-derived factor-1 (SDF-1) [228]. Moreover,
myofibroblasts-derived SDF-1 recruits endothelial progenitor cells into tumors,
thereby stimulating neoangiogenesis [229]. Additionally, VEGF protects
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endothelial cells from cell death and sustains angiogenesis by increasing Bcl-2
expression [198]. Herein, OC-derived extracellular Bcl-2 facilitated aberrant
endothelial tube formation, suggesting a paracrine pathway in which Bcl-2
functions to further enhance ovarian tumor progression (Figure 23).
Paradoxically, then, while tumor cells stimulate angiogenic factors that enhance
tumor growth and survival (i.e. through LPA upregulation of VEGF), dysregulated
tumor-mediated angiogenesis, potentially, in part, due to extracellular Bcl-2,
leads to aberrant vasculature, contributing to ascites formation and dissemination
of tumor cells. Taken together these findings provide more information about
cross-talk between tumor and endothelial cells that is essential for perpetuation
of tumor growth. Due to the heterogeneous population of stromal cell
components in ovarian tumors and the various cell types on which LPA, VEGF,
and Bcl-2 act, further OC 3D culture or animal model studies are warranted to
better understand how these proteins interact to modulate normal and/or
abnormal angiogenesis in vivo.
As previously mentioned, the lack of a diagnostic screening tool
contributes to the poor prognosis associated with OC. Ideally, the diagnostic test
would be minimally invasive, utilizing serum, or completely non-invasive, using
urine, and would provide a sensitivity, specificity, and positive predictive value
higher than that of CA125. Proteomics-based technology is at the forefront in
discovery of novel biomarkers for development of an early stage OC diagnostic
tool. Over the years, several serum proteins have been proposed as potential
biomarkers for OC including HE4[230], LPA [89], osteopontin [231], mesothelin
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Figure 23. Schematic representation of LPA-induced Bcl-2 overexpression
and secretion in OC cell leading to novel actions of secreted Bcl-2 on
endothelial cells. Our lab has previously shown that LPA induces telomerase
activity in a VEGF-dependent manner which can be inhibited by Vitamin E.
Chapter 3 showed that LPA increased Bcl-2 expression and secretion in OC cells
in a transcription-dependent manner. Extracellular Bcl-2 was then shown to
promote aberrant tube formation by inhibition of endothelial cell migration.
Chapter 4 showed that secreted Bcl-2 could be detected in urine of OC patients.
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[232], apolipoprotein A1[233], transthyretin [233], and transferrin [233]. While
urinary biomarkers have been used for diagnosis and prognosis of urological
malignancies for some time, urinary biomarkers for OC have recently piqued
interest due to the presence of fewer confounding proteins and improved protein
stability in urine compared to serum [234]. Recently, mesothelin [208],
angiostatin [235], and HE4 [236] have been identified as promising urinary
biomarkers for early stage OC. Additionally, urine metabolites have been
implicated in detection of early stage breast and OC [237], suggesting
metabolomics as another useful tool in the quest for cancer biomarkers. Despite
the promise of these studies, no single biomarker, or combination of markers,
has exhibited the criteria required to be designated as diagnostic marker(s) for
OC. Bcl-2 secretion by OC cells in vitro herein suggested that Bcl-2 secreted by
OC cells in vivo could be detected in bodily fluids and be clinically useful. I found
elevated urinary Bcl-2 levels in women with OC. Notably, urinary Bcl-2 was
elevated in samples from patients with both early and late stage OC, and was
complementary when compared to CA125 levels in parallel. Additionally, urinary
Bcl-2 was significantly lower in benign samples versus cancer samples. Other
apoptosis-related proteins found in urine include inhibin and activin, with
implications as a biomarker for severe pre-eclampsia in pregnant women [238],
and a risk assessment tool for hypoxic ischemic encephalopathy in newborns
[239], respectively. Altogether, these findings suggest that urinary Bcl-2, alone,
or in combination with other biomarkers may be a non-invasive, cost-effective
screening tool for OCs, including those at early stages.
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Collectively, this study demonstrates that Bcl-2 plays multifaceted roles in
OC progression and may be a potential biomarker to improve detection of early
stage OC. Hence, further understanding of the mechanisms by which Bcl-2
regulates the growth of OC cells and affects tumor angiogenesis through its antiapoptotic and extra anti-apoptotic functions will lead to improved diagnostic and
treatment strategies for OC.
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